Review

Cynanchum auriculatum Royle ex Wight., Cynanchum bungei Decne. and Cynanchum wilfordii (Maxim.) Hemsl.: Current Research and Prospects

Lu Wang 1,†, Fujie Cai 1,†, Wei Zhao 1, Jinli Tian 1, Degang Kong 1, Xiaohui Sun 1, Qing Liu 1, Yu'er Chen 1, Ying An 1, Fulin Wang 1, Xue Liu 1, Yi Wu 2 and Honglei Zhou 1,‡

1 College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; superlu77799@163.com (L.W.); Caifj1234@163.com (F.C.); w17862951781@163.com (W.Z.); tianjinli1998@163.com (J.T.); magicalgang@163.com (D.K.); sun_xiaohui@126.com (X.S.); Lq9775725@163.com (Q.L.); cyrl0495597136@163.com (Y.C.); anying323@163.com (Y.A.); qingdianxinxing@163.com (F.W.); bxsh24844284@163.com (X.L.)
2 Institute of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; wuyi2001cn@njau.edu.cn

† These authors contributed equally to this work.

Abstract: Cynanchum auriculatum Royle ex Wight. (CA), Cynanchum bungei Decne. (CB) and Cynanchum wilfordii (Maxim.) Hemsl. (CW) are three close species belonging to the Asclepiadaceous family, and their dry roots as the bioactive part have been revealed to exhibit anti-tumor, neuroprotection, organ protection, reducing liver lipid and blood lipid, immunomodulatory, anti-inflammatory, and other activities. Until 2021, phytochemistry investigations have uncovered 232 compounds isolated from three species, which could be classified into C21-steroids, acetophenones, terpenoids, and alkaloids. In this review, the morphology characteristics, species identification, and the relationship of botany, extraction, and the separation of chemical constituents, along with the molecular mechanism and pharmacokinetics of bioactive constituents of three species, are summarized for the first time, and their phytochemistry, pharmacology, and clinical safety are also updated. Moreover, the direction and limitation of current research on three species is also discussed.

Keywords: Cynanchum auriculatum Royle ex Wight.; Cynanchum bungei Decne.; Cynanchum wilfordii (Maxim.) Hemsl.; caudatin; cynandione A

1. Introduction

Cynanchum auriculatum Royle ex Wight. (CA), Cynanchum bungei Decne. (CB) and Cynanchum wilfordii (Maxim.) Hemsl. (CW) are three related species, commonly known as “Baishouwu”, and locals also call CA “Binhai baishouwu”, CB “Taishan baishouwu”, as well as CW “Paeksuo or Paekhasuo” [1–3]. Among them, CA and CW are mainly distributed in China, Japan, and Korea; while CB is concentrated in China, such as Shandong, Henan, Hebei, and Gansu provinces [4,5]. Current study has unraveled that CA, CB, and CW displayed high medicinal value, exactly as CA21-steroids were found to exhibit strong anti-tumor activity mainly involving hepatoma, breast cancer, and human glioma; while acetophenones and crude extracts of three species were revealed to exert immunomodulatory, hepatoprotection, anti-inflammatory, and anti-depressant activities [6]. Moreover, planting CA was able to bring high economic benefits, as it could be processed into flower tea and starch to be applied to the food industry [7]. There is a long history of medicinal use for the three species. CB was firstly recorded in the “Heshouwu Biography” from the Tang Dynasty, which explained that the red was a male called “Heshouwu”, the white was a female called “Baishouwu” [8]. Additionally, the nourishing blood, hepatoprotection, and strengthening kidney effects of CW were firstly

Molecules 2021, 26, 7065. https://doi.org/10.3390/molecules26237065 https://www.mdpi.com/journal/molecules
recorded in the “Compendium of Herbology” in Ming Dynasty [9]. At present, CA, CB, and CW have been served as traditional medicinal plants in China, Japan, and Korea, and they have been registered in “New Chinese Medicinal Herbal” [6]. Furthermore, a gas chromatography-mass spectrometer analysis revealed that there were different chemical constituents and biological activities in three species [10]. However, in traditional use, the phenomenon of mixing three species and unprecise pharmacology records in classic books were common due to the lack of scientific data at that time. Intriguingly, current study has addressed the above issues through several experiments, which contributed to helping us to apply them scientifically. It is worth noting that their application is not limited to individual species; as a matter of fact, they could be available to combine with other herbs to effectively treat common diseases. For instance, CW combined with Arctium lappa L. (Compositae) and Dioscorea opposite Thunb (Dioscoreaceae) were revealed to exhibit a potent suppressive effect on vascular and hepatic inflammation in mice fed a high fructose diet [11].

According to the published references, botany, phytochemistry, pharmacology, molecular mechanism, and the pharmacokinetics of bioactive constituents, as well as the clinical safety of CA, CB and CW, were compiled comprehensively in this review. Furthermore, we also proposed some suggestions regarding the limitation of three species study, aiming to provide a reference for relevant researchers.

2. Botany

2.1. Morphological Characteristics

CA: The roots are plump, and appear cylindrical and tuberous with a brownish-yellow surface. Its stems and leaves are covered with microscopic hairs, and leaves are oval, 4–12 cm long, and 4–10 cm wide. There are about 30 flowers with a soft hairy inner surface in individual, appearing white and oval-shaped. Moreover, its follicles double in lanceolate with 8 cm long and 1 cm in diameter. Normally, its flowering period is 6–9 months, and the fruit period is 7–11 months. CB: The roots are cylindrical or irregular masses with the brown-white surface, existing mostly 3–6 in number. The stems are slender with microhairs, and the leaves are halberd-shaped, 3–8 cm long, and 1–5 cm wide at the base. The calyx lobes are needle-shaped, and the corolla appears white or yellow-green with a soft hairy inner surface. The seed apex has numerous white filaments about 4 cm long. Its flowering period is 6–7 months, and its fruit period is 7–10 months. CW: The roots are spindle shaped and gray-brown, appearing about 10 cm long and 2 cm in diameter. The stems are slender with soft hair to cover, and leaves are ovate, 5–6 cm long, and 2–4 cm wide. There are about 15–20 flowers in the individual with soft hairs outside the calyx, and the corolla is yellowish, showing an oblong shape. Its follicles are single-born and needle-shaped, 12 cm long, and 1 cm in diameter. The seed is egg-shaped with a dark brown surface. Its flowering period is 5–9 months, and its fruit period is 7–10 months. The morphological characteristics of CA, CB and CW are displayed in Figure 1.

2.2. Identification of CA, CB and CW

A survey reported that there was a serious phenomenon to mix among CA, CB and CW in Korean and Chinese markets due to their similarities in appearance [12]. At present, the methods of chemical analysis and molecular markers have been conducted to differentiate them. The chemical analysis mainly involving UV, IR, HPLC, MS, NMR, and other techniques, is subjected to obtain typical chemical markers or unique information data to distinguish close species. For example, in the genus of Cynanchum, axasterol acetate, metaplexigenin, and stigmasterol were only isolated from CA, suggesting they could be recognized as chemotaxonomic markers to differentiate CA and the other two species [13]. Equally, a study revealed that conduritol F had the potential to be developed into a chemical marker to distinguish CA and CW, evidenced by its H-5 and H-6 signals being well-separated from other signals by the analysis of quantitative NMR [14]. It is noteworthy that alkaloids isolated from three species were all from CA, which could be
used as chemical markers to distinguish CA from the other two species [13,15,16]. In terms of unique information data, a study unraveled that CA and CW were available to analyze by the terahertz spectroscopic, leading to CW having a higher time delay than CA, which indicated it was an efficient method to differentiate related species based on their differences of permittivity [17]. Another study reported that paper cone spray ionization combined with MS contributed to rapidly determining chemical signatures of CA and CW, which could be efficiently applied to distinguish similar herbs [18].

![Morphological characteristics of CA, CB and CW](image)

**Figure 1.** Morphological characteristics of CA, CB and CW.

Molecular markers based on inter-individual nucleotide sequence variation that are universally found in the ribosomes and chloroplasts can directly reflect a specific DNA fragment in the genome of an organism or population at the DNA level [19]. They can not only accurately and efficiently differentiate similar species, but also be applied to distinguish pure and heterozygote species [20]. Currently, different primers are combined with PCR enabled specific DNA fragments to amplify, which is conducive to confirming the unique molecular markers of plants. A study reported that unique fragments of CA and CW combined with PCR were subjected to obtain characterized amplification region markers to distinguish them [21]. Another study revealed that molecular makers of CA and CW were obtained by their fragments united with conventional polymerase chain reaction PCR and real-time fluorescence quantitative PCR technology [22]. Notably, the appearance of internal transcribed spacer 2 made for reaching identification rates of 90.8% and 87.4% at the species level by BLAST and nearest distance methods, respectively, leading to an effective method to distinguish medicinal plants in the genus Cynanchum [23]. Nonetheless, to our knowledge, there was no report regarding molecular markers of CB in the previous study, and therefore further investigation was needed to find different molecular markers among CB and the other two species.

### 2.3. Relationship of CA, CB and CW

As we all know, common chemical constituents are often isolated from plants that have close relationships with each other, which can reveal their chemotaxonomic significance to some extent. For example, caudatin, 2,4-dihydroxyacetophenone, 2,5-dihydroxyacetophenone, 4-hydroxyacetophenone, and baishouwubenzophenone were all isolated from CA, CB and CW, indicating there were close relationships among them [24–29]. C_{21}-steroids (deacetylmetaplexigenin, rostratamine, wilfoside C1G, cynanauriculoside E, kidjoranin, cyanauriculoside A, wilfoside M1N), acetophenones (cynandione A–B, cynandione E), and other compounds (leucaethermolt, sucinie acid, sucrose, methyleugenol) were all obtained
from CA and CW, which might strengthen the relationship between them [5,27,28,30–41]. Bungeiside C, bungeiside D and 2-O-β-laminaribiosyl-4-hydroxyacetophenone were obtained from CB and CW, thereby revealing their close relationship between them [42,43]. Consequently, the chemotaxonomic significance of some compounds isolated from CA, CB and CW might support their close relationships, but more evidence was still needed.

Current determination of the relationship among CA, CB, and CW is concentrated on the method of the molecular marker, owing to its precise and scientific characters. Among three species, CA and CW were revealed to be the most closely related based on the analysis of the reported chloroplast genome [44]. Moreover, CW was demonstrated to have a close relationship with Asclepias nivea L. (Apocynaceae) and Asclepias syriaca L. (Apocynaceae) based on their mitochondrial genome [45,46]. Subsequently, compared with the genome of Asclepias syriaca L., CA was also demonstrated to be like Asclepias syriaca L., revealing their close relationship to some extent [47]. Unfortunately, few species were uncovered to be similar to CA, CB and CW, and therefore more evidence should be demanded to illustrate their close relationships with other herbs, which contributed to discovering their alternatives and related species.

3. Phytochemistry

3.1. Extraction and Separation

Extraction and separation are the basis of phytochemistry in medicinal plants, and consequently selecting efficient extraction methods and optimizing extraction conditions are of great interest in this direction [48]. Currently, systematic extraction was conducted to unravel chemical constituents of CA, CB and CW, which are characterized by versatility, efficiency, and convenience [4]. The steps are shown as follows: first, their roots are ground into powder to extract, using ethanol or methyl alcohol reflux in an extractor while setting an appropriate time and temperature, to obtain an extracting solution. Second, the extracting solution is extracted with reagents of different polarities, such as petroleum ether, dichloromethane, ethyl acetate, and n-butanol, to yield extracts of different polarities. Third, the extracts are concentrated and separated by elution on silica gel columns combined with reagents of different polarities to obtain different monomer components. Sometime it is necessary to purify different fractions by gel column, microporous resin, and preparative liquid phases. Finally, the chemical structure and formula of monomeric components are determined by UV, IR, MS, and NMR. Strikingly, if we want to obtain polysaccharide components, the roots need to be extracted by water decoction to obtain water extracts, and the subsequent purification operations will be carried out [49].

The optimization of the extraction is a key step in the phytochemistry study, which is beneficial to increase the extraction rate of the isolated components by changing the conditions and methods [50]. High-speed counter-current chromatography (HSCC) has been extensively applied to the separation and purification of acetophenones [51]. On the one hand, baishouwubenzophenone, 4-hydroxyacetophenone, 2,4-dihydroxy-acetophenone, and 2,5-dihydroxyacetophenone could be rapidly determined by HSCC, owing to its excellent reproducibility and high-separation efficiency [52]. On the other hand, components with similar structures, low concentration, and high polarity, such as bungeiside-A, bungeiside-B, and baishouwubenzophenone, could also be isolated by HSCC [53]. Furthermore, pressurized liquid extraction combined with a Box-Behnken design optimization was applied to the extraction of CB, resulting in it could be recognized as an efficient method to isolate acetophenones [54]. A study established an aqueous ionic liquid comprising three kinds of l-alkyl-3-methylimidazolium, and optimized ultrasound parameters including ionic liquid concentration, solvent to solid ratio, power, particle size, temperature, and extraction time, leading to a high extraction rate of acetophenones [24]. For other compounds, C21-steroids of CA were optimized to yield 49% content by single-factor orthogonal, and the best extraction conditions were revealed to be 95% ethanol and refluxed twice for 1.5 h each [55]. Polysaccharide yield of CA was optimized to reach 1.35% by single-factor with response surface methodology, and the best parameters were displayed as follows: liquid
to material ratio was 22:1 mL/g, ultrasonic time was 44 min, ultrasonic power was 350 W, and the ultrasonic temperature was 52 °C [56].

3.2. Chemical Constituents

232 compounds have been isolated from CA, CB, and CW as of October 2021, including 171 C21-steroids, 28 acetophenones, 12 terpenoids, 6 alkaloids, and 15 others. Of note, C21-steroid compounds were the main presences, of which caudatin and its derivatives as primary bioactive constituents have been revealed to exhibit remarkable anti-tumor activity, representing typical chemical and pharmacological features of three species [6]. Besides, acetophenones were the second metabolites in three species, of which cynandione A as the major bioactive compound has been demonstrated to exhibit extensive pharmacological activities, such as neuroprotection and hepatoprotection, which were characterized by healthcare activity [57,58]. Furthermore, reports regarding biological activities of terpenoids, alkaloids, and other constituents were refined, owing to their numbers being limited, which prompted us to explore more chemical constituents in the future.

3.2.1. C21-Steroids

It was reported that C21-steroid compounds isolated from CA, CB, and CW focused on chloroform and ethyl acetate fractions of crude extracts, and the content of root tuber was higher than root bark [59]. C21-steroid compounds are a class of steroid derivatives containing 21 carbon atoms, whose basic backbone is pregnane or their isomer [60]. Caudatin and kidjoranin were primary core families in pregnane glycosides, characterized by the neutral loss of ikemamic acid molecule (128 Da) and cinnamic acid (148 Da) from the precursor ion, respectively [61]. Crystalline and neutral substances of amorphous powder are primary states in C21-steroid compounds, with certain optical rotatory, and slightly soluble in water. Pregnane (I), seco-pregnane (II), trihydroxypregnane (III) are representative skeletons in C21-steroid compounds of three species, of which skeleton I is the main form. In skeleton I, A/B and B/C rings are trans-configurations and the C/D ring is the cis configuration. Skeleton a and b are representative structures in skeleton I, of which C10 in skeleton a connects with hydrogen, while skeleton b does not. At the C3 position, OH connected by monosaccharide, such as 2-deoxy digitalis, diginose, glucose, digitoxose, cymarose, and single OH, are primary to form the C21-glycoside [6]. Generally, C5 and C6 are double bond, C8 and C14 links with β-OH, C12 links with β-OH or ester group connected by OH and organic acid, C17 has more α conformation than β in the side chain, and C20 connects with carbonyl and ester group. These patterns are displayed in representative compounds, such as caudatin, caudatin-2,6-dideoxy-3-O-β-D-cymaropyranoside, cynabungigenin C, aauriculoside A, kidjoranin 3-O-β-digitoxopyranoside, gagaminine, qingyangshengenin, wilfoside C3N, wilfoside KIN, cnyscaccatol N. However, some peculiar compounds such as metaplexigenin, caudatin-3-O-β-cymaropyranoside, 12β-O-(4-hydroxybenzoyl)-8β,14β,17β-trihydroxy pregn-2,5-diene-20-one, eleutherosidea do not exhibit these patterns. In the skeleton II, C8 links with the carbonyl group, C14 links with the carbonyl group or β-OH, C12 connects with the phenyl acrylate, and C20 connects with the acetate group, such as cynabungoside A-C, wilfoside G, and cyanouricularoside F. In the skeleton III, C12 and C14 form epoxy ether and C17 connects with phenyl acrylate in the side chain, such as 17β-O-cinnamoyl-3β, 8β,14β-trihydroxy pregn-12,20-ether.

Previous biological investigations have revealed that caudatin, kidjoranin, qingyangshengenin, gagaminin, and their derivatives exhibited remarkable anti-tumor and antioxidant activities [62–64]. Furthermore, the biosynthesis pathway of C21-steroids was illustrated by Figure 2 based on relevant references, which was conducive to clarifying their roles in the living organism in the prospective study [65–67]. However, the number of bioactive constituents of C21-steroids is not much, and further pharmacological study should be carried out. Representative structures of C21-steroid compounds isolated from CA, CB, and CW are displayed in Figure 3.
Figure 2. Biosynthesis pathway of C_{21}-steroids. (Note: AACT: acetoacetyl-CoA thiolase, HMGS: 3-hydroxy-3-methylglutaryl-CoA synthase, PMK: phosphomevalonate kinase, IDI: isopentenyldiphosphate isomerase, GDS: geranyl diphosphate synthase, FDS: farnesyl diphosphate synthase, SS: squalene synthase, CAS: cycloartenol synthase, SMT: sterol methyltransferase, SCCE: side-chain cleaving enzyme, 3βSD: 3β-hydroxysteroiddehydrogenase, 3KSI: 3-ketosteroidisomerase).
Figure 3. Cont.
3.2.2. Acetophenones

Acetophenone is the simplest aromatic compound composed of the benzene ring and ketone carbonyl, presenting a colorless or light-yellow liquid, and it is generally found in the volatile oil of plants [68]. Normally, OH groups at C2 and C4 connect with sugar groups among acetophenones isolated from CA, CB, and CW, such as bungeiside A-D and picein.

**Figure 3.** Representative structures of C21-steroid compounds isolated from CA, CB, and CW. Pregnane (I), seco-pregnane (II), trihydroxypregnane (III).
2,4-dihydroxyacetophenone and 2,5-dihydroxyacetophenones links with biphenyl-like structures, such as cynandione A and cynwilforone A–C. Additionally, cynandione A as the primary bioactive compound in acetophenones has been uncovered to exert obvious neuroprotection and hepatoprotection, reducing liver lipid and blood lipid effects \([57,69–71]\). However, bioactive compounds of acetophenones of CA, CB, and CW were focused on cynandione A, and consequently more compounds with biological properties should be determined in the prospective study. Representative structures of acetophenone compounds isolated from CA, CB and CW were displayed in Figure 4.

![Acetophenone](image)

**Figure 4.** Representative structures of acetophenone compounds isolated from CA, CB and CW.
3.2.3. Terpenoids and Alkaloids

Terpenoids are important secondary metabolites commonly found in the plant kingdom, and they are olefins with isoprene as the basic unit \[72\]. According to the number of basic skeletal structures, they can be divided into monoterpenes, sesquiterpenes, diterpenes, and triterpenes. Generally, monoterpenes and sesquiterpenes are volatile oily liquids with a special odor, whereas diterpenes and triterpenes are solid crystals \[73\]. Notably, sesquiterpenes, such as wilfolides A and wilfolides B, along with triterpenes such as 28α-homo-β-amyrin acetate, cycloartenol, taraxaslerol acetate, and betulinic acid, are main presences in three species \[13,30,74\].

Alkaloids are nitrogen-containing basic organic substances primarily found in plants, containing nitrogen elements in the ring, exhibiting obvious biological activities in general \[75\]. Normally, they mainly existed in pyridine type, such as 3-hydroxypyridine, 3-hydroxy-2-methylpyridine, and 2-pyridinemethanol,5-hydroxy-(6CI,9CI) \[15\]. However, the references regarding the bioactive activity of alkaloids and terpenoids isolated from three species were scarce, requiring further study to unravel their pharmacological effects. Representative structures of terpenoid and alkaloid compounds isolated from CA, CB, and CW were displayed in Figure 5.

![Structures of Terpenoids and Alkaloids](image)

**Figure 5.** Representative structures of terpenoid and alkaloid compounds isolated from CA, CB, and CW.
3.2.4. Others

Polysaccharide is a polymer carbohydrate composed of more than 10 monosaccharides, which can be divided into homopolysaccharide and heteropolysaccharide based on the constituents of different monosaccharides [76]. It was reported that three heteropolysaccharides with molecular weights of 28,000, 51,000, and 11,700 of CA were determined to be composed of rhamnose, arabinose, xylose, mannose, galactose, and glucose [77]. The current study has revealed that polysaccharides of three species exhibited anti-inflammatory, antioxidant, immunomodulatory effects, but their structures have not been determined [78–80]. In addition, coumarins, lignans, and phenolic acids were also isolated from CA, CB, and CW, but their pharmacological effects have not been reported in the previous study. Consequently, further study should be conducted to identify exact structures of polysaccharides and explore potential biological activities of other constituents. C_{21}-steroids, acetophenones, terpenoids, alkaloids, and other compounds were summarized in Tables 1–5, respectively.

Table 1. C_{21}-steroids glycosides compounds isolated from CA, CB and CW.

| Number | Compounds | Species | References |
|--------|-----------|---------|------------|
| 1      | Caudatin  | CA CB CW | [25–27]    |
| 2      | Qingyangshengenin | CA | [31]        |
| 3      | Deacetylnaplexigenin | CA CW | [31,32]    |
| 4      | Rostratamine | CA CW | [31,32]    |
| 5      | Gagaminine | CA | [31]        |
| 6      | Daucosterol | CA | [31]        |
| 7      | Caudatin-3-O-β-D-digitoxopyranoside | CA | [31]        |
| 8      | Caudatin-3-O-β-D-cyamaropyranosyl(1→4)-β-D-digitoxopyranoside | CA | [31]        |
| 9      | Caudatin 3-O-β-D-cyamaropyranosyl(1→4)-β-D-cyamaropyranoside | CA | [31]        |
| 10     | Otophylloside B | CA | [31]        |
| 11     | Caudatin 3-O-β-D-oleandropyranosyl(1→4)-β-D-digitoxopyranosyl(1→4)-β-D-cyamaropyranoside | CA | [31]        |
| 12     | Gagaminine3-O-α-L-cympopyranosyl(1→4)-β-D-cympopyranosyl(1→4)-β-D-cympopyranoside | CA | [31]        |
| 13     | Auriculoses A | CA | [81]        |
| 14     | Auriculoses B | CA | [81]        |
| 15     | Cyanoauriculose C | CA | [82]        |
| 16     | Cyanoauriculose D | CA | [82]        |
| 17     | Cyanoauriculose E | CA | [82]        |
| 18     | Cyanauculose II | CA | [82]        |
| 19     | Wilfoside K1N  | CA | [82]        |
| 20     | Auriculose IV | CA | [82]        |
| 21     | Kidjolanin | CA | [83]        |
| 22     | 3-Formyloxymetaplexigenin | CA | [84]        |
| 23     | Metaplexigenin | CA | [84]        |
| 24     | Auriculose I  | CA | [33]        |
Table 1. Cont.

| Number | Compounds                                                                 | Species | References |
|--------|---------------------------------------------------------------------------|---------|------------|
| 25     | Auriculoside II                                                           | CA      | [33]       |
| 26     | Auriculoside III                                                          | CA      | [33]       |
| 27     | Wilfoside C1G                                                             | CA CW   | [33]       |
| 28     | Cynanacuriculoside I                                                      | CA      | [33]       |
| 29     | Cynauricuoside A                                                          | CA      | [33]       |
| 30     | Gagaminin3-O-β-l-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-digitoxopyranoside | CB      | [85]       |
| 31     | Gagaminin3-O-β-L-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside | CB      | [85]       |
| 32     | 12-O-nicotinylsarcostin3-O-β-l-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside | CB      | [85]       |
| 33     | Penupogenin3-O-β-D-glucopyranosyl-(1→4)-β-l-cymaropyranosyl-(1→4)-β-D-cymaropyranoside | CB      | [85]       |
| 34     | 12-O-acetyllysarcotin3-O-β-l-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-l-cymaropyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranoside | CB      | [85]       |
| 35     | 12-O-acetyllysarcotin3-O-β-l-cymaropyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-l-cymaropyranosyl-(1→4)-β-D-digitoxopyranoside | CB      | [85]       |
| 36     | Cynabungoside A                                                           | CB CW   | [26,86]    |
| 37     | Cynabungoside B                                                           | CB      | [86]       |
| 38     | Cynabungoside C                                                           | CB      | [86]       |
| 39     | Cynabungolide                                                             | CB      | [86]       |
| 40     | Cynabungone                                                               | CB      | [86]       |
| 41     | Wilfoside C1N                                                             | CB      | [86]       |
| 42     | Wilfolide A                                                               | CB      | [86]       |
| 43     | Deacylmetaplexigenin3-O-α-cymaropyranosyl-(1→4)-β-cymaropyranosyl-(1→4)-α-cymaropyranosyl-(1→4)-β-cymaropyranosyl-(1→4)-β-cymaropyranoside | CB      | [86]       |
| 44     | Cynanbungeinoside A                                                       | CB      | [87]       |
| Number | Compounds                                                                 | Species | References |
|--------|---------------------------------------------------------------------------|---------|------------|
| 45     | Cynanbungeinoside B                                                       | CB      | [87]       |
| 46     | Cynanbungeinoside C                                                       | CB      | [87]       |
| 47     | Cynanbungeinoside D                                                       | CB      | [87]       |
| 48     | Cynanbungeinoside E                                                       | CB      | [87]       |
| 49     | Cynanbungeinoside F                                                       | CB      | [87]       |
| 50     | Wilfoside B                                                               | CW      | [88]       |
| 51     | Wilfoside C                                                               | CW      | [88]       |
| 52     | Wilfoside D                                                               | CW      | [88]       |
| 53     | Wilfoside E                                                               | CW      | [88]       |
| 54     | Wilfoside F                                                               | CW      | [88]       |
| 55     | Wilfoside G                                                               | CW      | [88]       |
| 56     | Wilfoside H                                                               | CW      | [88]       |
| 57     | 20-O-salicyl-kidjoranin                                                   | CW      | [32]       |
| 58     | 12β-O-(4-hydroxybenzoyl)-8β,14β,17β-trihydroxypregn2,5-diene-20-one       | CW      | [32]       |
| 59     | 3-O-methyl-caudatin                                                       | CW      | [32]       |
| 60     | 20-O-(4-hydroxybenzoyl)-kidjoranin                                        | CW      | [32]       |
| 61     | 20-O-vanilloyl-kidjoranin                                                 | CW      | [32]       |
| 62     | 12-O-vanilloyl-deacymetaplexigenin                                        | CW      | [32]       |
| 63     | 17β-O-cinnamoyl-3ß,8ß,14β-trihydroxypregn-12,20-ether                     | CW      | [32]       |
| 64     | Deacymetaplexigenin                                                       | CW      | [32]       |
| 65     | 12-O-benzoyl-deacymetaplexigenin                                          | CW      | [32]       |
| 66     | 12β-O-benzoyl8ß,14ß,17ß-trihydroxypregn-2,5-diene-20-one                  | CW      | [32]       |
| 67     | Sarcostin                                                                 | CW      | [32]       |
| 68     | Deaclycynanchogenin                                                       | CW      | [32]       |
| 69     | Kidjoranine3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB      | [89]       |
| 70     | Caudatin3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB      | [89]       |
| 71     | Kidjoranine3-O-β-D-glucopyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB      | [89]       |
| 72     | O-nicotinoyl-20-O-cinnamonylsarcostin-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-digitoxyopyranoside | CB      | [89]       |
| Number | Compounds | Species | References |
|--------|-----------|---------|------------|
| 73     | Penupogenin3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-digitoxopyranoside | CB | [89] |
| 74     | Kidjoranine3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-digitoxopyranoside | CB | [89] |
| 75     | Caudatin3-O-β-D-glucopyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 76     | 12-O-benzoylethymetaplexigenin3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 77     | Caudatin3-O-β-D-glucopyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 78     | Caudatin3-O-α-L-cymaropyranosyl(1→4)-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 79     | Caudatin3-O-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 80     | Kidjoranine3-O-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 81     | Kidjoranine3-O-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 82     | Caudatin3-O-β-D-cymaropyranosyl(1→4)-α-L-diginopyranosyl(1→4)-β-D-cymaropyranoside | CB | [89] |
| 83     | O-benzoylethymetaplexigenin | CB | [89] |
| 84     | 12-O-acetyl-20-O-(2-methylbutanoyl)-sarcostin | CB | [89] |
| 85     | 20-O-Acetyl-penupogenin | CB | [89] |
| 86     | Gracigenin | CB | [89] |
| 87     | 8,14-seco-caudatin | CB | [89] |
| 88     | Penupogenin | CB | [89] |
| 89     | (20S)-12-cinnamoyloxy-20-acetyloxy-3,5,17-trihydroxy-8,14-seco-5,17-pregn-6-ene-8,14-dione | CB | [89] |
| 90     | Isoikemagenin | CB | [89] |
| Number | Compounds                                                                 | Species | References      |
|--------|---------------------------------------------------------------------------|---------|-----------------|
| 91     | O-cinnamoyl-20-O-(S)-(+)−α-methylbutyryl−sarcostin                         | CB      | [89]            |
| 92     | 12-O-cinnamoyl-20-O-(R)-(−)−α-methylbutyrylsarcostin                       | CB      | [89]            |
| 93     | Cynanauriculoside C                                                       | CA      | [27]            |
| 94     | Cynanauriculoside D                                                       | CA      | [27]            |
| 95     | Cynanauriculoside E                                                       | CA CW   | [27,34]         |
| 96     | Otophylloside L                                                           | CA      | [27]            |
| 97     | Wilfoside C3N                                                             | CA      | [35]            |
| 98     | Kidjoranin                                                                | CA CW   | [35]            |
| 99     | Cynanauriculoside I                                                       | CA      | [35]            |
| 100    | Cynanauriculoside II                                                      | CA      | [35]            |
| 101    | Cyanoauriculoside F                                                       | CA      | [82]            |
| 102    | Cyanoauriculoside G                                                       | CA      | [82]            |
| 103    | Cyanoauriculoside H                                                       | CA      | [82]            |
| 104    | 3-O-α-L-cymaropyranosyl-(1→4)-β-Deymaropyranosyl-(1→4)-α-L-digimopyranosyl-(1→4)-β-D-cymaropyranoside | CA      | [82]            |
| 105    | Wilfoside D1N                                                             | CA      | [82]            |
| 106    | Cyanoauriculoside A                                                       | CA CW   | [36]            |
| 107    | Cyanoauriculoside B                                                       | CA      | [36]            |
| 108    | Cynsaccatol Q                                                             | CA      | [90]            |
| 109    | Saccatol K                                                                | CA      | [90]            |
| 110    | Cynanbungeigenin C                                                        | CB      | [91]            |
| 111    | Cynanbungeigenin D                                                        | CB      | [91]            |
| 112    | Wilfoside A                                                                | CW      | [88]            |
| 113    | Wilfoside C1G                                                              | CA      | [92]            |
| 114    | Cynauriculoside C                                                         | CA      | [92]            |
| 115    | Caudatin-2,6-dideoxy-3-O-methy-β-D-cymaropyranoside                       | CA      | [92]            |
| 116    | Kidjoranin 3-O-adigimopyranosyl-(1→4)-β-cymaropyranoside                  | CA      | [64]            |
| 117    | Kidjoranin 3-O-β-digitoxopyranoside                                        | CA      | [64]            |
| 118    | Caudatin 3-O-β-cymaropyranoside                                           | CA      | [64]            |
| 119    | Auriculoside A                                                             | CA      | [93]            |
| 120    | Wilfoside C1GG                                                             | CW      | [26]            |
| 121    | Wilfoside C1G                                                              | CW      | [26]            |
| 122    | Wilfoside K1GG                                                             | CW      | [26]            |
| 123    | Wilfoside M1N                                                              | CA CW   | [34,37]         |
| 124    | Cynauricoside A                                                            | CW      | [37]            |
| 125    | Cynauricoside B                                                            | CW      | [37]            |
| 126    | Cynauricoside C                                                            | CW      | [37]            |
Table 1. Cont.

| Number | Compounds                                      | Species | References |
|--------|-----------------------------------------------|---------|------------|
| 127    | Cynauricoside D                              | CW      | [37]       |
| 128    | Cynauricoside E                              | CW      | [37]       |
| 129    | Cynauricoside F                              | CW      | [37]       |
| 130    | Cynauricoside G                              | CW      | [37]       |
| 131    | Cynauricoside H                              | CW      | [37]       |
| 132    | Cynauricoside I                              | CW      | [37]       |
| 133    | Eleutherosidea                               | CA      | [38]       |
| 134    | Caudatin-3-O-β-cymaropyranoside              | CA      | [59]       |
| 135    | Cynauricoside B                             | CA      | [94]       |
| 136    | Gagaminin-3-O-α-L-cymaropyranosyl-          | CW      | [74]       |
|        | (1→4)-β-D-cymaropyranosyl-(1→4)-α-L-digino |         |            |
|        | pyranosyl-(1→4)-β-D-digitoxopyranoside       |         |            |
| 137    | Cynawilfoside A                             | CW      | [74]       |
| 138    | Cynawilfoside B                             | CW      | [74]       |
| 139    | Cynawilfoside C                             | CW      | [74]       |
| 140    | Cynawilfoside D                             | CW      | [74]       |
| 141    | Cynawilfoside E                             | CW      | [74]       |
| 142    | Cynawilfoside F                             | CW      | [74]       |
| 143    | Cynawilfoside G                             | CW      | [74]       |
| 144    | Cynawilfoside H                             | CW      | [74]       |
| 145    | Cynawilfoside I                             | CW      | [74]       |
| 146    | Gagaminin-3-O-β-D-cymaropyranosyl-          | CW      | [95]       |
|        | (1→4)-β-Doleandropyranosyl-(1→4)-β-D-       |         |            |
|        | cymaropyranosyl-(1→4)-β-D-cymaropyranosid   |         |            |
| 147    | Lneolon                                       | CW      | [96]       |
| 148    | Saccatol D                                  | CA      | [97]       |
| 149    | Saccatol E                                  | CA      | [97]       |
| 150    | Saccatol F                                  | CA      | [97]       |
| 151    | Saccatol G                                  | CA      | [97]       |
| 152    | Saccatol H                                  | CA      | [97]       |
| 153    | Saccatol I                                  | CA      | [97]       |
| 154    | Saccatol J                                  | CA      | [97]       |
| 155    | Saccato K                                   | CA      | [97]       |
| 156    | Cynsaccatol I                               | CA      | [97]       |
| 157    | Cynsaccatol J                               | CA      | [97]       |
| 158    | Cynsaccatol K                               | CA      | [97]       |
| 159    | Cynsaccatol L                               | CA      | [97]       |
| 160    | Cynsaccatol M                               | CA      | [97]       |
| 161    | Cynsaccatol N                               | CA      | [97]       |
| 162    | Cynsaccatol O                               | CA      | [97]       |
| 163    | Cynsaccatol P                               | CA      | [97]       |
Table 1. Cont.

| Number | Compounds      | Species | References |
|--------|----------------|---------|------------|
| 164    | Cynsaccatol Q  | CA      | [97]       |
| 165    | Cynsaccatol R  | CA      | [97]       |
| 166    | Cynsaccatol S  | CA      | [97]       |
| 167    | Cynsaccatol T  | CA      | [97]       |
| 168    | Cynsaccatol U  | CA      | [97]       |
| 169    | Cynsaccatol V  | CA      | [97]       |
| 170    | Cynsaccatol W  | CA      | [97]       |
| 171    | Gagamine       | CA      | [98]       |

Table 2. Acetophenone compounds isolated from CA, CB and CW.

| Number | Compounds                                               | Species | References |
|--------|---------------------------------------------------------|---------|------------|
| 172    | 2,4-Dihydroxyacetophenone                              | CA CB CW | [24,28]  |
| 173    | 2,5-Dihydroxyacetophenone                              | CA CB CW | [24,28]  |
| 174    | 4-Hydroxyacetophenone                                  | CA CB CW | [24,28]  |
| 175    | Cynandione A                                           | CA CW   | [28,30]   |
| 176    | Cynandione B                                           | CA CW   | [39]      |
| 177    | Cynandione E                                           | CA CW   | [39]      |
| 178    | Baishouwubenzophenone                                  | CA CB CW | [24,29]  |
| 179    | Cynwilforone A                                         | CW      | [99]      |
| 180    | Cynwilforone B                                         | CW      | [99]      |
| 181    | Cynwilforone C                                         | CW      | [99]      |
| 182    | 2-O-β-laminaribiosyl-4-hydroxyacetophenone             | CB CW   | [42,43]   |
| 183    | Bungeiside-C                                           | CB CW   | [42,43]   |
| 184    | Bungeiside-D                                           | CB CW   | [42,43]   |
| 185    | (+) Cynwilforone D                                     | CW      | [100]     |
| 186    | (-) Cynwilforone D                                     | CW      | [100]     |
| 187    | (+) Cynwilforone E                                     | CW      | [100]     |
| 188    | (-) Cynwilforone E                                     | CW      | [100]     |
| 189    | (+) Cynwilforone F                                     | CW      | [100]     |
| 190    | (-) Cynwilforone F                                     | CW      | [100]     |
| 191    | Cynwilforone G                                         | CW      | [100]     |
| 192    | Bungeiside-A                                           | CB      | [101]     |
| 193    | Bungeiside-B                                           | CB      | [101]     |
| 194    | Picein                                                  | CA      | [15]      |
| 195    | 4′-Hydroxy-3′-methoxyacetophenone                       | CW      | [40]      |
| 196    | 1-(2-Hydroxy-4,5-dimethoxyphenyl) ethanone             | CA      | [102]     |
| 197    | Cynanchone A                                           | CW      | [103]     |
| 198    | 2,4-Dihydroxy-5-methoxyacetophenone                    | CA      | [104]     |
| 199    | Cynantetrone                                           | CA      | [105]     |
Table 3. Terpenoids compounds isolated from CA, CB, and CW.

| Number | Compounds                      | Species | References |
|--------|--------------------------------|---------|------------|
| 200    | β-sitosterol                   | CA      | [38]       |
| 201    | β-amyrin acetate               | CA      | [38]       |
| 202    | Wilfolides A                   | CW      | [74]       |
| 203    | Wilfolides B                   | CW      | [74]       |
| 204    | Cycloartenol                   | CA      | [13]       |
| 205    | 28α-Homo-β-amyrin acetate      | CA      | [13]       |
| 206    | 11α, 12α-Epoxytaraxer-14-en-3β-yl-acetate | CA | [13] |
| 207    | δ-Amyrine acetate              | CA      | [13]       |
| 208    | Taraxasler acetate             | CA      | [30]       |
| 209    | Betulinic acid                 | CA      | [30]       |
| 210    | Oleanolic acid                 | CA      | [106]      |
| 211    | Lupeol                         | CB      | [107]      |

Table 4. Alkaloids compounds isolated from CA, CB, and CW.

| Number | Compounds                                      | Species | References |
|--------|-----------------------------------------------|---------|------------|
| 212    | 3-Hydroxypyridine                             | CA      | [15]       |
| 213    | 3-Hydroxy-2-methylpyridine                    | CA      | [15]       |
| 214    | 2-Pyridinemethanol, 5-hydroxy                | CA      | [15]       |
| 215    | 1H-imidazole-5-carboxylic acid                | CA      | [13]       |
| 216    | 6-[(β-D-xylopyranosyl) methyl]-3-pyridinol   | CA      | [16]       |
| 217    | 2-Methyl-6-(2′,3′,4′-trihydroxybutyl)-pyrazine | CA      | [15]       |

Table 5. Other compounds isolated from CA, CB, and CW.

| Number | Compounds                                      | Species | References |
|--------|-----------------------------------------------|---------|------------|
| 218    | Ferulic acid methylester                      | CA      | [38]       |
| 219    | Islariciresinol                               | CA      | [15]       |
| 220    | Vomifoliol                                    | CA      | [15]       |
| 221    | n-Hexacos-5,8,11-trienoic acid                | CA      | [13]       |
| 222    | Isocopelatin                                  | CA      | [15]       |
| 223    | Isofraxidin                                   | CA      | [15]       |
| 224    | Adenosine                                     | CA      | [15]       |
| 225    | (+)-isolariciresinol                          | CA      | [15]       |
| 226    | 4,4-dimethyl heptanedioic acid                | CA      | [15]       |
| 227    | Leucanthemitol                                | CA CW   | [5,41]     |
| 228    | Suceinie acid                                 | CA CW   | [5,41]     |
| 229    | Sucrose                                       | CA CW   | [38,40]    |
| 230    | Methyleugenol                                 | CA CW   | [5]        |
| 231    | Conduritol F                                  | CW      | [5]        |
| 232    | 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione | CW | [14] |

4. Pharmacology

4.1. Anti-Tumor Activity

To start with, as to hepatic carcinoma, a study revealed that hepatocellular mice induced by diethylnitrosamine model were subjected to the treatment of caudatin of CA
at the dose of 50 mg/kg, resulting in liver nodule being reduced, and the inflammatory lesion was attenuated obviously, and the further study revealed that restoration of the dysregulated unfolded protein response was responsible for the anti-hepatoma effect of caudatin [25]. In vitro assay, caudatin-2,6-dideoxy-3-O-methyl-β-D-cymaropyranoside and caudatin isolated from CA during the dose of 0.48–300 μM were able to exhibit suppressive effects on SMMC7721 cells with IC50 values of 13.49 and 24.95 μM, respectively [92]. C21 steroidal glycoside of CA within the dose of 45 μg/mL was uncovered to inhibit the proliferation and migration rate of HepG2 cells, leading to apoptotic morphology with nuclear crinkling, hemizygous, or circular shape in a concentration-dependent manner [108]. The ethanol extract of CA at the doses of 2 and 4 mg/kg was demonstrated to remarkably inhibit inflammation, liver fibrosis, and hepatocellular carcinoma of mice induced by diethylnitrosamine, and its mechanism was associated with the attenuated expression of TL4 as well as the downregulation of MyD88, TRAF6, NF-κBp65, TGF-β1 and α-SMA [109].

For breast cancer, in vivo assay, caudatin of CA at the dosage of 10 mg/kg was demonstrated to inhibit proliferation and formation of breast cancer stem cells, and the further study revealed that it induced ubiquitin-dependent glucocorticoid receptor degradation in stem cancer to block Yes-associated protein nuclear accumulation and transcriptional signaling of the target gene [110]. Aauriculoside A, a C21 steroidal glycoside isolated from CA, was subjected to test MCF-7 cells, resulting in the rate of apoptosis reaching 18.5% at the dose of 40 μg/mL, which was characterized by morphological apoptotic of cytoplasmic contraction and nuclear chromatin condensation [93]. As for uterine cancer, caudatin isolated from CA at the concentration ranging from 25 to 100 μmol/L was able to inhibit the proliferation, migration, and induce apoptosis of HeLa cells and endometrial carcinoma cell line [62]. In addition, kidjoranin 3-O-α-digingo.pyranosyl-(1→4)-β-cymaropyranoside and kidjoranin 3-O-β-digitoxyopyranoside, caudatin 3-O-β-cymaropyranoside isolated from CA at the concentrations of 10 mM were revealed to exert significant cytotoxic effects on HeLa, SMMC-7721, and MCF-7 cells with IC50 values ranging from 8.6 to 58.5 μM, suggesting they have extensive suppressive effects on cervical cancer, hepatoma, and breast cancer [64]. Concerning human glioma, in vitro assay, caudatin isolated from CB at the dose of 100 μmol/L enabled the activity of human glioma U251 cells to reach 28.2% in a time-dose dependent manner with IC50 value of 52.1 μM [111]. Cynanbungeigin C and cyananbungeigin D isolated from CB at the dosage of 50 mg/kg were revealed to block Hedgehog pathway-dependent medulloblastoma by regulating the level of Gli, suggesting they were potential to be developed into new therapeutic agents of human glioma and malignancies [91].

For gastric cancer, the growth of AGS and HGC-27 cells was effectively inhibited with the treatment of caudatin of CB during the dose of 25–100 μM in a time-dose dependent manner, and their IC50 values were 54.92 and 65.98 μmol/L, respectively [112]. Caudatin 3-O-β-D-cymaropyranosyl-(1→4)-β-D-oleandropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranoside isolated from CA within the dose of 80 μM enabled the inhibition rate of HGC-27 cells to reach 93.3% in time-dose dependent manner after 72 h, and its IC50 value was 15 μM [113]. Additionally, a study reported that wilfoside C3N of CA within the concentration of 16 mg/mL was subjected to treat esophageal cancer ECA109 cells In vitro assay, resulting in 21.3% apoptosis in a time-dose dependent manner [114]. Another study revealed that caudatin of CB within the dosage of 100 μg/mL obviously attenuated proliferation and migration of alveolar basal epithelial cell line A549, and eventually inhibited growth and angiogenesis of alveolar basal epithelial cells [115].

4.2. Neuroprotection and Organ Protection

Intriguingly, neuroprotection, hepatoprotection, gastric protection, and skin protection activities have been uncovered from three species in the previous study, which were characterized by healthcare effects. For neuroprotection, it was reported that cyanandione A isolated from CA at the dosage of 30 mg/kg was able to reduce the area of cerebral infarction of mice by 7.2% in...
a dose-dependent manner after 72 h, which was correlated with the activity to attenuate glutamate-induced cytotoxicity [116]. Cynsaccatol Q and saccatol K of CA during the concentrations of 0.1–10 µM were subjected to treat PC12 cells induced by H2O2, and as a result, they played a neuroprotective role against oxidative damage by decreasing intracellular ROS and Ca2+ levels and inhibiting cell apoptosis [90]. A study reported that (+) cynwiforone F and (−) cynwiforone F of CW at the doses of 10 µM possessed a protective effect on SH-SY5Y cells treated with Aβ oligomer, revealing they were capable of increasing cell survival to 76.34% and 81.65%, respectively [100]. Four C21 steroidal glycosides, cynsaccatols I, N, O, S isolated from CA at the dosages of 1 µM possessed suppressive effects on PC12 cells apoptosis by Annexin V-FITC/PI double staining assay with flow cytometry [97].

With respect to hepatoprotection, in hepatocytes in a mice model, induced by CCl4, cynandione A isolated from CW at the dose of 50 µM, were damaged by regulating the levels of glutathione, superoxide dismutase, catalase, as well as glutathione reductase essential to combat against oxidative stress in cellular defense [69]. C21 steroidal glycoside of CA at the doses of 4 and 8 g/kg were able to decrease the levels of AST and ALT, improve SOD activity, and reduce malondialdehyde content in the in vivo assay, which significantly inhibited hepatocyte edema and degeneration induced by CCl4 [117]. Moreover, polysaccharide of CA at the dosage ranging from 100 to 500 mg/kg was capable of reducing serum ALT and AST levels in mice with hepatic injury induced by CCl4, revealing its feasibility to exert hepatoprotection effect [118].

For gastric protection, a study reported that ethanol extracts of CA, CB, and CW at the dosages of 150 and 68 mg/kg possessed potent protective effects on gastric injury induced by ethanol and indomethacin, as well as gastric acid secretion induced by histamine in rats [119]. Another study revealed that water extracts of CW at the dosage of 0.72 g/kg enabled serum gastric motility, gastrin, gastric emptying rate, and small intestinal propulsion rate to increase, as well as vasoactive intestinal peptide levels to decrease, which promoted gastric empty and small intestinal propulsion [120]. Additionally, 2,5-dihydroxyacetophenone isolated from CB at the dose of 0.4 mM was able to inhibit melanin synthesis and tyrosinase activity of mice melanoma cells stimulated by 3-isobutyl-1-methylxanthine and increase the mean skin lightening index, indicating its potential use as a therapeutic human skin protector [121].

4.3. Immunoregulation Activity

It was reported that cyclosporine A as a positive control, nine C21-steroid compounds including cynabungosides A-C, wilfoside K1N, wilfoside C1N, 12-O-nicotinylsarcostin-3-O-β-lcamaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-digcynaropyranosyl-(1→4)-β-D-cymaropyranoside, deacetylmetaplexigenin 3-Ó-α-cymaropyranosyl-(1→4)-β-cymaropyranosyl-(1→4)-α-cymaropyranosyl-(1→4)-β-cymaropyranosyl-(1→4)-β-cymaropyranoside, cynabugone, and cyanabungolide within the doses of 40 µM were demonstrated to have potent suppressive effects on T lymphocytes proliferation with IC50 values ranging from 1.63 to 40.93 µM [86]. Notably, as to the above compounds except for cynabugone, other eight compounds were uncovered to significantly inhibit the proliferation of B lymphocytes, with IC50 values ranging from 0.64 to 38.80 µM [86]. Moreover, a study reported that the crude polysaccharide of CA at the doses of 100 and 200 mg/kg was able to improve the expression of nitric oxide, and immunostimulatory cytokines such as interleukin-6 and TNF-α in RAW264.7 macrophages activated by recombinant interferon-γ prime [78]. Meanwhile, it could also recover body weight, immune organ weight, natural killer cell activity, as well as the proliferation of T and B lymphocytes of mice immunosuppressed by cyclophosphamide in vivo assay [78].

4.4. Reducing Liver Lipid and Blood Lipid

Cynandione A isolated from CW at the dose of 100 µM was revealed to promote the differentiation of adipocyte 3T3-L1 cells by enhancing the expression of lipogenic
transcription factors, brown adipocyte-associated genes, and beige adipocyte-associated
genes [70]. In a mice model with nonalcoholic fatty liver disease, the ethanol extract of CW
at the doses of 100 and 200 mg/kg was revealed to reduce hepatic fat accumulation and
hepatosplenomegaly damage, and its mechanism was related to the suppressive effects on
COX-2, NF-κB, and p38 MAPK [122].

A study reported that ethanol extract of CW at the dose of 0.2 g/kg was capable of
increasing HDL-cholesterol level and reducing atherosclerotic index of mice with hyper-
cholesterolemia disease, possessing its activity of reducing blood lipid to some extent [123].
Another study uncovered that 2,5-dihydroxyacetophenone and cynandione A isolated
from CW during the concentrations of 10–40 µM were able to alleviate atherosclerosis by
inhibiting LDL oxidation and glycosylation [71].

4.5. Anti-Inflammatory Activity

Cynandione A of CW within the dose of 200 µM was able to significantly decrease
the levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in mice with
LPS, and the further study demonstrated that its mechanism was associated with sup-
pressive effects on NF-κB and MAPK signaling pathways [124]. It was reported that
4-hydroxyacetophenone, cynandione A, and ethanol extract of CW within the concentra-
tion of 200 µg/mL were found to have a significant suppressive effect on human aor-
tic smooth muscle cells stimulated by TNF-α, illustrating they could be used for the
treatment of vascular inflammatory diseases [125]. The crude polysaccharide of CW at
100 and 200 mg/kg was demonstrated to improve the pathological features and reduce
the production of serum pro-inflammatory cytokines in mice induced by colitis, as well as
inhibit several cytokines and enzymes correlated with inflammation by attenuating NF-κB
and protein kinase activated by mitogen in RAW264.7 macrophages [79]. C21 steroidal
glycoside of CA within the dose of 45 µg/mL could protect against oxidative toxicity and
inflammatory damage in L02 cells induced by H2O2 through upregulating the expression
of Nrf2 and HO-1 via the NF-κB signaling pathway [126].

4.6. Antioxidant Activity

A study uncovered that the polysaccharide of CA within the dose of 12.5 µg/mL
exhibited scavenging activity against ABTS, DPPH, and superoxide anion radical in vitro
antioxidant models, with IC50 values of 0.1232, 0.5543, and 0.5881 mg/mL, respectively [80].
Moreover, it was revealed to increase the content of antioxidant enzyme SOD and non-
enzymatic antioxidant GSH in oxidatively damaged cells, which contributed to reduc-
ing oxidative stress and achieving intracellular antioxidant effects [61]. Gagamine,
a C21 steroidal compound isolated from CW, was revealed to have potent suppressive
effects on aldehyde oxidase activity and lipid peroxidation at the dose of 2 mg/L in vitro
assay [63]. Cynandione A, cynandione B, cynandione E, cynanchone A, and cynantetron-
e isolated from CA at the doses of 1 µM were revealed to exert potent antioxidant activity
through inhibiting oxidative damage induced by H2O2 [105].

4.7. Antidepressant Activity

It was reported that a methanol extract of CA at the dose of 10 mg/L possessed a 71.1%
inhibition rate with an IC50 value of 5.2 mg/L, revealing its promising antidepressant role
in therapy agents [127]. A study regarded fluoxetine at the dose of 20 mg/kg as the posi-
tive control and revealed cynanauriculosides C-E, cynauricuoside C, and otophyllloside L
isolated from CA were able to exhibit potent antidepressant activity at the doses of 50 mg/kg in vivo assay, of which cynanauriculosides D was close to the fluoxetine [27].

4.8. Antifungal and Antiviral Activities

A study reported that caudatin and qingyangshen of CW as leading compounds were ap-
plied to synthesize four derivates of C21-steroids, including 3-O-(methanesulfonyl)caudatin,
3-O-(nicotinic)caudatin, 3,17-O-Di(4-methoxy-cinnamoyl)qingyangshengenin, 3,17-O-
Di(p-anisoyl)qingyangshengenin, and they were revealed to exhibit significant suppressive effects on the growth of sclerotinia sclerotiorum at the dosages of 50 µg/mL by mycelial growth rate assay, with IC$_{50}$ values of 0.0084, 0.0049, 0.0053, and 0.0034 µM, respectively [128]. It was reported that wilfoside C1N, wilfoside C1G, and wilfoside C1GG isolated from CW at the doses of 63 µg/mL were able to possess potent suppressive effects on the activity of Blumeria graminis f. sp. Hordei, suggesting they might be used as prominent fungicides to control powdery mildew [26]. A study on CW found that its ethyl acetate fraction of ethanol extract at the dose of 40 g/mL possessed potent antiviral activity against the influenza virus with an IC$_{50}$ value of 27.84 µg/mL, uncovering its potential antiviral application in the future [129].

4.9. Others

In addition to the above pharmacological effects, hypoglycemic, anti-angiogenic, anti-prostatic, anti-leukemic, anti-epileptic, appetite suppression, aphrodisiac, menopause suppression, anti-prostatic hyperplasia, and bone-strengthening effects have been uncovered from CA, CB, and CW. A study reported that cynandione A and cynwilforone A isolated from CW at the dosages of 40 µM enabled the suppressive rates of hepatic gluconeogenesis to reach 29.2% and 29.4%, respectively, and their mechanism were associated with the downregulation of PEPCK and G6P expressions [99]. Wilfoside K1N of CW at the dose of 10 µM displayed suppressive effects on the micro-vessel formation and tube formation of human umbilical vein endothelial cells, suggesting it was potential to be developed into a new anti-angiogenic agent [130]. A study on CW revealed that 20-O-salicyl-kidjoranin was able to have a significant cytotoxic effect on leukemia cells HL-60 with an IC$_{50}$ value of 6.72 µM, while qingyangshengenin and rostratamin possessed cytotoxic effects on leukemia cells K-562 and MCF-7, and their IC$_{50}$ values were 6.72 and 2.49 µM, respectively [32]. Cynawlfoloside A, cynauricoside A, wilfoside C1N, wilfoside K1N, and cyanoauriculoside G isolated from CW at the doses of 100 mg/kg possessed anti-epileptic effects on mice induced by maximal electroshock with ED$_{50}$ values of 48.5, 95.3, 124.1, 72.3, and 88.1 mg/kg, respectively [74]. Moreover, wilfoside C1N and wilfoside K1N isolated from CA at the doses of 50 mg/kg were able to decrease food consumption, water consumption, and weight of rats, revealing their potent anti-appetite effect [37]. Water extract of CW at the dose of 200 mg/kg was employed to improve motivation and libido of male Sprague Dawley rats to exert an aphrodisiac effect through stimulating the secretion of luteinizing hormone, follicle-stimulating hormone, and testosterone [131]. In ovariectomized mice, the water extract of CW at the concentration of 40 µg/mL was able to attenuate uterine atrophy and bone loss without changing the plasma estradiol concentration, as well as reduce plasma follicle-stimulating hormone, alkaline phosphatase, and osteocalcin to normal levels, revealing its feasibility to be developed into therapeutic agents for the prevention of menopausal syndrome in women [132]. In mice models with benign prostatic hyperplasia induced by testosterone, water extract of CW at the dose of 50 mg/kg could make prostate growth inhibition rate reach 54.5%, which was attributed to the suppressive effects on the expressions of androgen receptor, 5α-reductase, and B-cell lymphoma-2 [133]. Moreover, water extract of CW at the dose of 400 mg/kg was capable of enhancing the bone mineral density of mice with osteoclast differentiation and osteoporosis, accompanied by the decreased phosphatase, osteocalcin, and collagen type I C-telopeptide, and tartrate-resistant acid phosphatase levels [134]. Subsequently, it was also revealed to reduce bone marrow cells as well as increase bone mineral density and profile, suggesting it possessed a potent therapeutic effect on osteoporosis [135]. Chemical structures of bioactive compounds isolated from CA, CB, and CW are displayed in Figure 6. The pharmacological effects of bioactive compounds and extracts isolated from CA, CB, and CW are shown in Table 6.
Figure 6. Cont.
Figure 6. Cont.
Figure 6. Cont.
Figure 6. Chemical structures of bioactive compounds isolated from CA, CB and CW.

Table 6. Pharmacological effects of bioactive compounds and extracts isolated from CA, CB and CW.

| Number | Bioactive Constituents and Parts | Species | Pharmacology | References |
|--------|----------------------------------|---------|--------------|------------|
| 1      | Caudatin                         | CW      | Anti-hepatocellular carcinoma | [136] |
| 1      |                                  | CA      | Anti-breast cancer             | [110] |
| 1      |                                  | CA      | Anti-uterine cancer            | [62]  |
| 1      |                                  | CB      | Anti-human glioma              | [111] |
| 1      |                                  | CB      | Anti-gastric cancer            | [112] |
| 1      |                                  | CA      | Anti-lung cancer               | [115] |
| Number | Bioactive Constituents and Parts | Species | Pharmacology | References |
|--------|---------------------------------|---------|--------------|------------|
| 2      | Cynandione A                    | CA      | Neuroprotection | [57]       |
|        |                                 | CW      | Hepatoprotection | [58]       |
|        |                                 | CW      | Anti-inflammatory | [137]     |
|        |                                 | CW      | Reducing liver lipid | [70]     |
|        |                                 | CW      | Reducing blood lipid | [71]     |
|        |                                 | CW      | Hypoglycemic | [99]       |
| 3      | Wilfoside KIN                   | CW      | Anti-angiogenic | [130]     |
|        |                                 | CW      | Appetite suppression | [37]     |
| 4      | Aauriculosaide A                | CA      | Anti-breast cancer | [93]     |
| 5      | Caudatin-2,6-dideoxy-3-O-methy-β-D-cymaropyranoside | CA | Anti-hepatocellular carcinoma | [92] |
| 6      | Kidjoranin-3-O-α-diginopyranosyl-(1→4)-β-cymaropyranoside | CA | Anti-cervical cancer | [64] |
|        |                                 | CA      | Anti-hepatocellular carcinoma | [64] |
|        |                                 | CA      | Anti-breast cancer | [64]   |
| 7      | Kidjoranin-3-O-β-digitoxopyranoside | CA | Anti-cervical cancer | [64] |
|        |                                 | CA      | Anti-hepatocellular carcinoma | [64] |
|        |                                 | CA      | Anti-breast cancer | [64]   |
| 8      | Caudatin-3-O-β-cymaropyranoside  | CA      | Anti-cervical cancer | [64] |
|        |                                 | CA      | Anti-hepatocellular carcinoma | [64] |
|        |                                 | CA      | Anti-breast cancer | [64]   |
| 9      | Gagaminine                      | CW      | Antioxidant | [63]       |
| 10     | Cynandione B                    | CA      | Antioxidant | [105]      |
| 11     | Cynandione E                    | CA      | Antioxidant | [105]      |
| 12     | Cynanchone A                    | CA      | Antioxidant | [105]      |
| 13     | Cynantetone                     | CA      | Antioxidant | [105]      |
| 14     | Cynanbungeigenin C              | CB      | Anti-human glioma | [91]     |
| 15     | Cynanbungeigenin D              | CB      | Anti-human glioma | [91]     |
| 16     | Caudatin-3-O-β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranoside | CA | Anti-gastric cancer | [113] |
| 17     | Cynsaccatol Q                   | CA      | Neuroprotection | [90]       |
| 18     | Saccatol K                      | CA      | Neuroprotection | [90]       |
| 19     | Cynsaccatol I                   | CA      | Neuroprotection | [97]       |
| 20     | Cynsaccatol N                   | CA      | Neuroprotection | [97]       |
| 21     | Cynsaccatol O                   | CA      | Neuroprotection | [97]       |
| 22     | Cynsaccatol S                   | CA      | Neuroprotection | [97]       |
| 23     | (+) Cynwiforones F              | CW      | Neuroprotection | [100]     |
| 24     | (−) Cynwiforones F              | CW      | Neuroprotection | [100]     |
| 25     | Wilfoside C3N                   | CA      | Anti-esophageal cancer | [114] |
| 26     | Wilfoside C1N                   | CW      | Antifungal | [26]       |
|        |                                 | CB      | Immuno-regulation | [86]     |
|        |                                 | CW      | Anti-epileptic | [74]       |
|        |                                 | CA      | Appetite suppression | [37] |
| 27     | Wilfoside C1G                   | CW      | Antifungal | [26]       |
| 28     | Wilfoside C1GG                  | CW      | Antifungal | [26]       |
| Number | Bioactive Constituents and Parts | Species | Pharmacology | References |
|--------|---------------------------------|---------|--------------|------------|
| 29     | Cynanauriculoside C             | CA      | Antidepressant | [27]       |
| 30     | Cynanauriculoside D             | CA      | Antidepressant | [27]       |
| 31     | Cynanauriculoside E             | CA      | Antidepressant | [27]       |
| 32     | Otophylloside L                 | CA      | Antidepressant | [27]       |
| 33     | Cynauricoside C                 | CA      | Antidepressant | [27]       |
| 34     | Cynabungoside A                 | CB      | Immunoregulation | [86]      |
| 35     | Cynabungoside B                 | CB      | Immunoregulation | [86]      |
| 36     | Cynabungoside C                 | CB      | Immunoregulation | [86]      |
| 37     | 12-O-Nicotinoylsarcostin-3-O-β- l-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside | CB | Immunoregulation | [86] |
| 38     | Deacymetaplexigenin-3-O-α-cymaropyranosyl-(1→4)-β-cymaropyranosyl-(1→4)-β-cymaropyranoside | CB | Immunoregulation | [86] |
| 39     | Cynabungone                     | CB      | Immunoregulation | [86]      |
| 40     | Cynabungolide                   | CB      | Immunoregulation | [86]      |
| 41     | 2,5-Dihydroxyacetophenone       | CB, CW  | Skin protection, Reducing blood lipid | [121], [71] |
| 42     | 4-Hydroxyacetophenone           | CW      | Anti-inflammatory | [125]    |
| 43     | 20-O-Salicyl-kidjoranin         | CW      | Anti-leukemic   | [32]       |
| 44     | Qingyangshengenin               | CW      | Anti-leukemic   | [32]       |
| 45     | Rostratamin                     | CW      | Anti-leukemic   | [32]       |
| 46     | Cynwilforone A                  | CW      | Hypoglycemic    | [99]       |
| 47     | Cynwilfoside A                  | CW      | Anti-epileptic  | [74]       |
| 48     | Cynauricoside A                 | CW      | Anti-epileptic  | [74]       |
| 49     | Cyanoauriculoside G             | CW      | Anti-epileptic  | [74]       |
| 50     | C₂₁ steroidal glycoside         | CA, CA  | Hepatoprotection, Anti-inflammatory | [117], [126] |
| 51     | Polysaccharides                 | CW, CA, CA | Anti-inflammatory, Antioxidant, Menopause suppression, Hepatoprotection, Immunoregulation | [79], [80], [132], [118], [78] |
| 52     | Ethanol extract                 | CW, CA, CB, CW | Anti-hepatocellular carcinoma, Reducing blood lipid, Gastric protection, Reducing liver lipid, Antiviral effect | [25, 109], [123], [119], [122], [129] |
| 53     | Water extract                   | CW, CA, CA, CW | Anti-prostatic Hyperplasia, Aphrodisiac, Bone-strengthening | [133], [131], [134] |
| 54     | Methanol extract                | CA      | Antidepressant activity | [127]     |
5. Molecular Mechanism

Since phytochemicals are usually characterized by multi-pathways and multi-targets in the living organism, it is difficult for us to clarify their mechanisms comprehensively and clearly. Given that, we screened the representative molecular pathways and action factors of bioactive compounds and extracts in CA, CB, and CW to provide a convenient understanding for readers.

5.1. Cell Cycle Arrest

The cell cycle can be divided into G0, G1, S, G2, and M phases, and some bioactive compounds can inhibit their intracellular genomic DNA and block the process of mitosis to cause the suppressive effect on cell proliferation [138]. A study revealed that alveolar epithelial cell line A549 was blocked at the G0/G1 phase in a dose-dependent manner with the treatment of caudatin of CB within the concentration of 100 µg/mL, and its IC50 value was 121.1 mg/mL [115]. Gastric cancer cells AGS and HGC-27 were treated by caudatin of CB during the dose of 25–100 µM, and revealed that G1 to S phase metastasis was blocked in a dose-dependent manner through downregulating CDK2 protein levels [139]. Hepatocellular carcinoma SMMC-7721 cells were tested by caudatin of CA at the dose of 12.5µM, leading to the number of G2 cells having a significant increase than S phase in a time-dose dependent manner, which was attributed to blocking the transportation of the S to G2 phase [136]. A study concerning human glioma U251 and U87 cells reported that caudatin of CB during the dose of 25–100 µM triggered cell arrests of G0/G1 and S phases, which significantly inhibited the proliferation-related cell to upregulate p53, p2, and histone phosphorylation, as well as downregulated cyclinD1 [140]. When MCF-7 cells were treated by the auriculoside A of CA at the dosage of 40 µg/mL, the number of hepatocellular carcinoma MCF-7 cells was increased in G0/G1 phase whereas was decreased in S and G2/M phases, indicating that it enabled cell cycle arrest to locate in G0/G1 phase [93].

5.2. Triggering Cell Apoptosis

Cell apoptosis is an autonomous and ordered death to maintain the stability of the internal environment, characterized by cell volume contraction, chromatin condensation, shedding from its surrounding tissues, and phagocytosis with no inflammatory response from the organism [141]. Current research on CA, CB, and CW has revealed that the mechanism of cell apoptosis was associated with the bc-2 family and caspase family. In hepatocellular carcinoma HepG2 cells with the treatment of caudatin of CB during the dose of 25–100 µM, the expression of Bcl-2 was downregulated, whereas Bax expression was upregulated, accompanied by activation of caspase-3, -9, and polymerase [139]. C21-steroidal glycoside of CA at the dosage of 21.6 µM was subjected to treat gastric cancer SGC-7901 cells to cause a 43.2% apoptosis rate, and the further study revealed that it could trigger apoptosis through the caspase-3 dependent pathway [113]. A report uncovered that human glioma U251 and U87 cells were triggered with the treatment of caudatin during the dose of 25–100 µM in caspase-dependent apoptosis through mitochondrial dysfunction and reactive oxygen species production [111]. Additionally, wilfósde C3N isolated from CA during the dose of 2–32 µg/mL was able to trigger apoptosis of esophageal cancer ECA109 cells through triggering the release of cytochromes from mitochondria and activating caspase-9 receptors [114].

5.3. Effect on NF-κB Pathway

NF-κB is an important intracellular nuclear transcription factor that is mainly involved in anti-inflammatory, anti-tumor, and immunomodulatory effects in humans [142]. IκB including common IxBα and IxBβ, as an inhibitory protein of NF-κB, is normally combined with NF-κB to prevent NF-κB translocating into the nucleus when it was activated by bioactive constituents [143]. The suppressive effects on NF-κB contributed to enhancing the expression of IL-6, TNF-α, and IL-1β cytokines to treat inflammatory disease. Of note, current investigations regarding CA, CB, and CW have demonstrated that the NF-κB
pathway was primarily correlated with anti-inflammatory effects. For example, cynandione A of CW within the dose of 50 µM was uncovered to possess a potent suppressive effect on BV-2 microglial cells induced by LPS, and its mechanism was demonstrated to be related to the suppressive effect on the phosphorylation of IkBα and the translocation of nuclear factor NF-κB to BV-2 cells [144]. A study revealed that caudatin of CA at the concentration of 100 µmol/L was able to inhibit the proliferation and migration of human cervical carcinoma cell lines and endometrial carcinoma cell lines through the TNFAIP1/NF-κB signaling pathway [62]. Another study on hepatocyte cell lines L02 induced by H2O2 revealed that C21-steroidal glycoside of CA within the dose of 45 µg/mL was able to protect them from oxidative toxicity and inflammatory damages by enhancing Nrf2 and HO-1 expression via the NF-κB signaling pathway [126].

5.4. Effect on MAPK Pathway

MAPK containing ERK, p38, JNK, and ERK5 subfamilies is an important transmitter from the cell surface to the interior of the nucleus, and it can be expressed in all eukaryotic cells involving in cell proliferation, differentiation, apoptosis, inflammation, and other activities [145]. In mice models with neurological disease, cynandione A of CW at the dose of 100 µM was able to upregulate the phosphorylation of MAPK including p38, ERK1/2, and JNK, thereby leading to promote β-endorphin expression and reduce neuropathic pathological pain [146]. In an investigation regarding TRAIL-induced apoptosis in human breast cancer cells, caudatin of CA within the concentration of 100 µg/mL contributed to promoting DR receptor expression to trigger apoptosis by increasing CHOP expression and phosphorylation of p38MAPK and JNK [147]. In mice fed with a high-fat and high-fructose diet, ethanol extract of CW at the dosages of 100 and 200 mg/kg could reduce fat accumulation and damage in the liver by inhibiting p38MAPK and AKT phosphorylation [122]. Primary human skin fibroblast and human keratinocyte models were established to uncover that polysaccharides of CW at the doses of 200 and 400 µg/mL could significantly suppress UVB-induced oxidative stress, connected with the mechanisms to downregulate MKK4-JNK, MEK-ERK, and MKK3/6-p38 phosphorylation [148].

5.5. Effect on Wnt/β-Catenin Pathway

The wnt/β-catenin pathway is commonly associated with cancer diseases, of which wnt is a secreted glycoprotein that leads to the accumulation of β-catenin, while β-catenin is a bifunctional protein that regulates cell-cell adhesion and the coordination of gene transcription to promote cell proliferation [149]. GSK3β is a key member of the wnt signaling pathway, and it often combines with β-catenin when wnt protein disappears. A study revealed that caudatin of CB within the concentration of 100 µg/mL could inhibit the growth of human alveolar carcinoma basal epithelial cells through the GSK3β/β-catenin pathway [115]. In gastric cancer HGC-27 cells, caudatin of CB at the dose ranging from 25 to 100 µM was able to decrease β-catenin expression that was caused by the downregulation of cyclinD1 and c-myc, suggesting wnt/β-catenin signaling pathway was correlated with the treatment of caudatin in gastric cancer [112]. Additionally, caudatin of CW during the dose of 12.5–50 µM was uncovered to inhibit GSK3β and β-catenin expression, which was attributed to the suppressive effect on wnt protein target genes COX-2, MMP2, and MMP9 [136].

5.6. Effect on Vascular Factor

Current research regarding CA, CB and CW revealed that developing therapeutic agents based on anti-angiogenesis and vascular protection were primary directions for the treatment of vascular disease. Anti-angiogenic therapy is a novel and effective method to treat the disease that was dependent on angiogenesis, while vascular protection was attributed to suppressive effects on VEGF and VCAM factors [150]. An anti-angiogenic study reported that caudatin of CA during the dose of 50–200 µM was able to inhibit proliferation, migration, invasion, and vascular formation of human umbilical vein endothelial cells by in-
terfering with the vascular endothelial growth pathway of VEGF-VEGFR2-AKT/FAK [151]. A study regarding vascular protection revealed that cynandione A of CW within the dose of 40 µM could effectively inhibit VCAM-1 expression in LPS-induced umbilical vein endothelial cells and human aortic smooth muscle cells stimulated by TNF-α [137]. Furthermore, in mice models fed with a high-fat/cholesterol diet, ethanol extract of CW at the dosage of 200 mg/kg was revealed to ameliorate hypertension and endothelial dysfunction through NO/cGMP signaling pathway, associated with the suppressive effect on ET-1, VCAM, and lesion formation, which could be applied to the treatment and prevention of atherosclerotic vascular disease [152]. Representative molecular mechanisms of bioactive compounds and extracts isolated from CA, CB, and CW were displayed in Figure 7.

Figure 7. Representative molecular mechanism of bioactive compounds and extracts isolated from CA, CB and CW. (Bioactive constituents: ①: Caudatin, ②: Cynandione A, ③: Wilfoside C3N, ④: Auriculoside A, ⑤: C_{21} steroidal glycoside of CA, ⑥: Ethanol extract of CW, ⑦: Polysaccharide of CW).
6. Pharmacokinetics

Pharmacokinetics is used to evaluate and explore quantification, absorption, distribution, and metabolism patterns of bioactive constituents in living organisms, which is an important criterion for evaluating potential new drugs [153]. However, bioactive constituents regarding pharmacokinetic of CA, CB, and CW are not enough and they are mainly concentrated on cynandione A, caudatin and its derivatives. It was reported that cynandione A of CW at the dosage of 2.5 mg/kg was employed to evaluate by LC-MS/MS method in vivo assay, resulting in retention time of 1.41 min and concentration range of 0.2–1000 ng/mL, good linearity with intra-day and inter-day, and precision and accuracy of NE in plasma and tissues less than 14.4%, suggesting it could be absorbed and distributed rapidly without long-term accumulation in mice tissue [154]. The determination of caudatin of CB at the dosage of 12 mg/kg was established in rats plasma by UPLC-MS/MS using carbamazepine as an internal standard, leading to good linearity in the concentration ranging from 2.5 to 300 ng/mL, as well as precision and accuracy of inter-day and intra-day were within 10% and 5%, respectively [155]. In mice with hepatoma induced by diethyl-nitrosamine, caudatin-2,6-dideoxy-3-O-methyl-β-D-cymaropyranoside of CA during the concentration of 0.1–10 µg/mL was subjected to test by UPLC-MS/MS method, resulting in a linear ranging from 5 to 500 ng/mL, and precision of inter-day and intra-day were within 8.5% and 9.1%, respectively, along with ±10.9% accuracy [156]. Another study determined metabolites of wilfoside C1N and wilfoside C3N of CB at the doses of 50 mg/kg in mice plasma and tumor homogenate by the analysis of LC-MS/MS, leading to wilfoside C3N having a better absorption than wilfoside C1N, which might be attributed to different lengths of sugar chain [157].

7. Clinical Safety

In 2015, a woman developed eosinophilic esophagitis after 2–3 weeks of repeated CW administration, which attracted widespread attention about the safety of CW. However, CW as a new dietary supplement has been approved by the US Food and Drug Administration for many years, and it has never been reported that there was serious side effect in the body after taking food containing CW. Unexpectedly, the case that repeated CW administration contributed to causing eosinophilic esophagitis has been confirmed by history, endoscopy, histology, and BAT methods [158]. Given that, clinical trials regarding the safety of CW administration have been established. In 2019, ethanol extracts of CW at the dosages of 300 and 600 mg/d were subjected to test 84 subjects in a randomized placebo-controlled trial, leading to some adverse events such as urinary discomfort, allergic reactions, vomiting, skin problems, and gastrointestinal discomfort [159]. However, all these events were mild reactions and not statistically significant. Subsequently, 64 subjects with high cholesterol were selected to take ethanol extract of CW at the dosages of 300 and 600 mg/d in 2020, resulting in four participants with emerging symptoms of blepharospasm, constipation, vomiting, and pruritus [160]. The manifestation of these symptoms was mild enough with low toxicity that no medication was required and there were no significant abnormalities based on the complete blood counts and blood chemistry results. According to the above cases, we found that CW possessed significant adverse effects when it was repeatedly administered, while there were no serious effects on the human body in a mild dose, suggesting it should be consumed in certain doses and not in excess. In previous pharmacological assays, bioactive constituents of CA, CB, and CW have not exerted obvious toxicity in vivo and vitro assays but lacked professional research on their toxicity. To our knowledge, there was no report regarding the clinical trial of CA and CB in the previous study. Consequently, it is necessary for us to establish clinical trials of CA and CB to test their safety, which contributed to developing the potential drugs in the future.

8. Conclusions and Prospects

First, botany study based on chemical analysis and molecular techniques revealed that there were close relationships among CA, CB, and CW. At the same time, they could
also be identified by chemotaxonomic and molecular markers. However, there was a lack of molecular markers of CA and CW, and therefore molecular techniques of CB should be carried out in the future. Second, phytochemistry clarified 232 chemical compounds isolated from CA, CB, and CW, including C_{21} steroids, acetophenones, terpenoids, alkaloids, and others. Nevertheless, they were all only isolated from the roots of three species, and accordingly, more compounds should be found from their stems, leaves, and flowers. Third, pharmacology study uncovered that anti-tumor, neuroprotection, organ protection, reducing blood lipid and liver lipid, immunomodulatory, anti-inflammatory, anti-oxidant, anti-depressant, anti-fungal, and anti-viral effects in three species. Of note, relevant bioactive compounds are not many, emphasizing caudatin and cynandione A, and consequently more bioactive compounds should be uncovered by plenty of pharmacological experiments. Furthermore, concrete compounds of crude extracts with biological activities need to be further determined, which was conducive to clarifying their roles in the further pharmacological assay. Fourth, molecular mechanism study illustrated that cell cycle arrest, triggering cell apoptosis and wnt/β-catenin pathway are primary mechanisms of anti-tumor activity, while NF-κB pathway was responsible for anti-inflammatory activity. MAPK pathway and the role of vascular factor were representative mechanisms to exert neuroprotection and organ protection activities. Undoubtedly, the molecular mechanisms of bioactive compounds isolated from three species are mainly concentrated on typical pathways and targets, and consequently deeper study should be required to uncover new action pathways and targets, as well as explore their feasibilities to develop into new drugs. Fifth, pharmacokinetics study demonstrated that cynandione A, caudatin and its derivatives, were able to exert good absorption, distribution, and metabolism in the living organism. Sixth, clinical trials uncovered that there were no significant adverse effects in the mild dose of CW, but required us to strictly control the dose taken. Unfortunately, clinical trials on CA and CB have not been established, and the ethanol extract was not suitable for developing into new drugs. In the future, bioactive compounds of crude extract should be further confirmed, as well as more clinical trials on CA and CB should be also carried out.

Although there were no specialized clinical trials to prove the safety of caudatin and cynandione A, they were mainly obtained in ethanol extract and no relevant toxicity was reported in previous pharmacological experiments, which probably indicated that they have low toxicity to some extent, but the perspective needed to be proved by specialized toxicity tests in the prospective study. According to their pharmacological effects, molecular mechanism, pharmacokinetics, and clinical safety investigations, caudatin was potential to be developed into a new anti-tumor candidate, while cynandione A with extensive organ protection and neuroprotection activities might be made into a promising healthcare agent, but more evidence should be found to support that in the future. In this paper, the current research status of CA, CB, and CW was reviewed, which might be relevant for researchers to acquire a deeper understanding.

**Author Contributions:** L.W. and F.C. contributed equally to this work. L.W. and F.C.: data curation, writing-original draft and review & editing, methodology. W.Z., J.T., D.K., X.S. and Q.L.: data curation, investigation, formal analysis, writing-review & editing. Y.C., Y.A., F.W., X.L. and Y.W.: investigation, methodology, data curation. H.Z.: resources, supervision, writing-original draft. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by the Project of National Key Research and Development Program (2018YFC1707002) and Project of Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education (P201805), and General project of improving the guidance ability of graduate tutors in Shandong Provin (SDYY18047).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.
Acknowledgments: We would like to thank Wenhua Chen, Zhenzhen Zhang, Yanfei Ban, Khalid Rahman, Bingzhu Ye, Xiaolei Sun, Huiying Tan, Xiaohua Zheng, Hongyan Liu, Lingchuan Xu, Bin Yan, and Ting Han for providing the data.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds in this paper are available from the authors.

Abbreviations

UV: Ultraviolet spectrophotograph, IR: Infrared spectrophotograph, HPLC: High Performance Liquid Chromatography, MS: Mass Spectrum, NMR: Nuclear Magnetic Resonance Spectrometer, PCR: Polymerase Chain Reaction, BLAST: Basic Local Alignment Search Tool, ABTS: 2,2’-Azinobis(3-ethylbenzthiazoline-6-sulphonate), DPPH: 1,1-Diphenyl-2-picrylhydrazyl radical, 2,2-Diphenyl-1-(2,4,6-trinitrophenyl)hydrazyl, TNF-α: Tumor necrosis factor alpha, IL: Interleukin, NF-κB: Nuclear Factor kappa-B, MAPK: Mitogen-Activated Protein Kinase, VEGF: Vascular Endothelial Growth Factor, VCAM: Vascular Cell Adhesion Molecule, LPS: Lipopolysaccharide, LC: Liquid Chromatography, LDL: Low-Density Lipoprotein Cholesterol, HDL: High-density lipoprotein cholesterol.

References

1. Han, L.; Zhou, X.; Yang, M.; Zhou, L.; Deng, X.; Wei, S.; Wang, W.; Wang, Z.; Qiao, X.; Bai, C. Ethnobotany, Phytochemistry and Pharmacological Effects of Plants in Genus Cynanchum Linn. (Asclepiadaceae). Molecules 2018, 23, 1194. [CrossRef]
2. Yin, X.; Ding, S.F.; Shao, J.Z.; Wang, M.L.; Zhang, T.; Zhuang, Z.L.; Peng, Y.R. Research progress on Cynanchi bungei Radix. Chin. Tradit. Herbal Drugs 2019, 50, 992–1000.
3. Choi, D.H.; Lee, Y.J.; Kim, J.S.; Kang, D.G.; Lee, H.S. Cynanchum wilfordii ameliorates hypertension and endothelial dysfunction in rats fed with high fat/cholesterol diets. Immunopharmacol. Immunotoxicol. 2012, 34, 4–11. [CrossRef][PubMed]
4. Zhou, J.; Zhang, T.; Wang, Q.; Chen, J. Chromatographic fingerprint analysis of varietal differences among three species of Baishouwu and simultaneous analysis of three bioactive constituents by use of LC–DAD. Chromatographia 2008, 68, 213–218. [CrossRef]
5. Jiang, Y.; Choi, H.G.; Li, Y.; Park, Y.M.; Lee, J.H.; Kim, D.H.; Lee, J.H.; Son, J.K.; Na, M.; Lee, S.H. Chemical constituents of Cynanchum wilfordii and the chemotaxonomy of two species of the family Asclepiadaceae, C. wilfordii and C. auriculatum. Arch. Pharm. Res. 2011, 34, 2021–2027. [CrossRef][PubMed]
6. Chen, W.H.; Zhang, Z.Z.; Ban, Y.F.; Rahman, K.; Ye, B.Z.; Sun, X.L.; Tan, H.Y.; Zheng, X.H.; Liu, H.Y.; Xu, L.C.; et al. Cynanchum bungei Decne and its two related species for “Baishouwu”: A review on traditional uses, phytochemistry, and pharmacological activities. J. Ethnopharmacol. 2019, 243, 112110. [CrossRef]
7. Li, J.F. Present situation and Countermeasures of industrial development of Binhai baishouwu. South Chin. Agric. 2019, 13, 120–121.
8. Liang, P.; Zheng, J.S.; Zhao, Z.Z. Bencao literature investigation of Polygonum multiforum (Heshouwu). Chin. J. Chin. Mater. Med. 2016, 41, 4456–4461.
9. Liu, J.; Niu, J.M.; Zhao, J.H.; He, W.B.; Lv, B.X.; Li, Y.Q. Research Progress of Taishan Baishouwu. Guangdong Chem. Industry 2019, 46, 119–120.
10. Wu, C.D.; Zhang, M.; He, M.T.; Gu, M.F.; Lin, M.; Zhang, G. Selection of solvent for extraction of antioxidant components from Cynanchum auriculatum, Cynanchum bungei, and Cynanchum wilfordii roots. Food Sci. Nutr. 2019, 7, 1337–1343. [CrossRef]
11. Song, H.S.; Koo, H.J.; Park, B.K.; Kwon, J.E.; Jang, S.A.; Baek, H.J.; Kim, S.Y.; Lee, S.R.; Kang, S.C. The suppressive effect of the three-herb extract mixture on vascular and liver inflammation in atherogenic diet with high fructose-fed mice. Pharm. Biol. 2018, 56, 53–62. [CrossRef]
12. Sato-Masumoto, N.; Uchikura, T.; Sugiwaki, H.; Yoshimura, M.; Masada, S.; Atsumi, T.; Watanabe, M.; Tanaka, N.; Uchiyama, N.; Amakura, Y.; et al. Survey on the original plant species of crude drugs distributed as Cynanchi Wilfordii Radix and its related crude drugs in the Korean and Chinese Markets. Biol. Pharm. Bull. 2017, 40, 1693–1699. [CrossRef][PubMed]
13. Wang, X.J.; Lv, X.H.; Li, Z.L.; Qian, S.H.; Pu, S.B. Chemical constituents from the root bark of Cynanchum auriculatum. Biochem. Syst. Ecol. 2018, 81, 30–32. [CrossRef]
14. Jang, H.S.; Jeong, B.; Choi, S.Y.; Jang, G.H.; Park, K.C.; Kwon, Y.S.; Yang, H. Conduritol F, the discriminant marker between C. wilfordii and C. auriculatum by 1H NMR spectroscopy. Microchem. J. 2017, 135, 153–157. [CrossRef]
15. Zhang, B.; Yao, C.F.; Wang, Y.; Jiang, L.; Ma, X.; Sun, J.; Zhang, G.Q.; Li, Y.J. Chemical constituents in water fraction of Cynanchum auriculatum. Chin. Tradit. Herbal Drugs 2018, 49, 786–790.
16. Peng, X.; Wu, Y.Y.; Zhang, B.; Ma, X.; Sun, J.; Wang, G.C.; Li, Y.J. One new glycoalkaloid from the water-soluble fraction of Cynanchum wilfordii and its structure elucidation by terahertz spectroscopic analysis. Phytochem. Anal. 2018, 29, 472–475. [CrossRef]
18. Jun, G.; Park, T.M.; Cha, S. Fast and simple chemical fingerprinting analysis of medicinal herbs by Paper Cone Spray Ionization Mass Spectrometry (PCSI MS). Bull. Korean Chem. Soc. 2016, 37, 1337–1343. [CrossRef]
19. Jo, I.H.; Kim, Y.C.; Kim, D.H.; Kim, K.H.; Hyun, T.K.; Ryu, H.; Bang, K.H. Applications of molecular markers in the discrimination of Panax species and Korean ginseng cultivars (Panax ginseng). J. Ginseng Res. 2017, 41, 444–449. [CrossRef] [PubMed]
20. Han, E.H.; Cho, K.; Goo, Y.; Kim, M.; Shin, Y.W.; Kim, Y.H.; Lee, S.W. Development of molecular markers, based on chloroplast and ribosomal DNA sequences, to discriminate three popular medicinal plant species, Cynanchum wilfordii, Cynanchum auriculatum, and Polygonum multiflorum. Mol. Biol. Rep. 2016, 43, 323–332. [CrossRef]
21. Moon, B.C.; Choo, B.K.; Cheon, M.S.; Yoon, T.; Ji, Y.; Kim, B.B.; Lee, A.Y.; Kim, H.K. Rapid molecular authentication of three medicinal plant species, Cynanchum wilfordii, Cynanchum auriculatum, and Polygonum multiflorum (Fallopia multiflora), by the development of RAPD-derived SCAR markers and multiplex-PCR. Plant Biotechnol. Rep. 2010, 4, 1–7. [CrossRef]
22. Ryuk, J.A.; Lee, H.W.; Ju, Y.S.; Ko, B.S. Monitoring and identification of Cynanchum wilfordii and Cynanchum auriculatum by using molecular markers and real-time polymerase chain reaction. J. Korean Soc. Appl. Biol. Chem. 2014, 57, 245–251. [CrossRef]
23. Guo, M.Y.; Ren, L.; Fang, X.H. Inspecting the true identity of herbal materials from Cynanchum using ITS2 barcode. Front. Plant Sci. 2017, 8, 1945. [CrossRef] [PubMed]
24. Sun, Y.; Liu, Z.; Wang, J.; Yang, S.; Li, B.; Xu, N. Aqueous ionic liquid based ultrasonic assisted extraction of four acetophenones from the Chinese medicinal plant Cynanchum bungei Decne. Ultrason. Sonochem. 2013, 20, 180–186. [CrossRef] [PubMed]
25. Song, J.; Ding, W.; Liu, B.; Liu, D.; Xia, Z.; Zhang, L.; Cui, L.; Luo, Y.; Jia, X.; Feng, L. Anticancer effect of caudatin in diethylnitrosamine-induced hepatocarcinogenesis in rats. Mol. Med. Rep. 2020, 22, 697–706. [CrossRef]
26. Yoon, M.Y.; Choi, N.H.; Shin, M.S.; Yoon, T.; Ji, Y.; Kim, B.B.; Lee, A.Y.; Kim, H.K. Rapid molecular authentication of three medicinal plant species, Cynanchum wilfordii, Cynanchum auriculatum, and Polygonum multiflorum (Fallopia multiflora), by the development of RAPD-derived SCAR markers and multiplex-PCR. Plant Biotechnol. Rep. 2010, 4, 1–7. [CrossRef]
27. Yang, Q.X.; Ge, Y.C.; Huang, X.Y.; Sun, Q.Y. Cynanauriculoside C-E, three new antidepressant pregnane glycosides from Cynanchum auriculatum. Phytochem. Lett. 2011, 4, 170–175. [CrossRef]
28. Li, Y.; Piao, D.; Zhang, H.; Woo, M.H.; Lee, J.H.; Moon, D.C.; Lee, S.H.; Chang, H.W.; Son, J.K. Quality assessment and determination of the roots of Cynanchum auriculatum by HPLC-UV analysis. Arch. Pharm. Res. 2013, 36, 335–344. [CrossRef]
29. Wu, H.Y.; Chen, L.; Bian, Q.Y.; Wang, J. Determination of Acetophenone in Baishouwu by one assay and multiple evaluation method. Chin. Med. Mat. 2015, 38, 2339–2347.
30. Yin, M.; Chen, Y.; Wang, M.; Dong, Y.; Xia, B.; Feng, X. Chemical constituents of the root of Cynanchum auriculatum. Chin. Med. Mat. 2007, 30, 1245–1247.
31. Guo, N.; Li, X.P.; Xu, Z.; Han, W.J.; Lin, X.T.; Xu, X.X. Isolation and identification of C21 steroids from Cynanchum auriculatum. J. Shenyang Pharm. Univ. 2016, 33, 28–33. [CrossRef]
32. Huang, L.J.; Wang, B.; Zhang, J.X.; Yan, C.; Mu, S.Z.; Hao, X.J. Studies on cytotoxic pregnane sapogenins from Cynanchum wilfordii. Fitoterapia 2015, 101, 107–116. [CrossRef] [PubMed]
33. Yao, N.; Gu, X.J.; Li, Y.B. C21 steroids study on antitumor activity of steroidal saponins from Baishouwu. Chin. Tradit. Pat. Med. 2010, 32, 1975–1978.
34. Lee, G.; Choi, C.-Y.; Jun, W. Effects of aqueous extracts of Cynanchum wilfordii in rat models for postmenopausal hot flush. Prev. Nutr. Food Sci. 2016, 21, 373–377. [CrossRef] [PubMed]
35. Gu, X.J.; Yao, N.; Qian, S.H.; Li, Y.B.; Li, P. Four new C21 steroidal glycosides from the roots of Cynanchum auriculatum. Acta Pharm. Sin. 2009, 92, 88–97. [CrossRef]
36. Teng, H.L.; Lu, Y.; Li, J.; Yang, G.Z.; Mei, Z.N. Two new steroidal glycosides from the root of Cynanchum auriculatum. Chin. Chem. Lett. 2011, 22, 77–80. [CrossRef]
37. Liu, S.; Chen, Z.; Wu, J.; Wang, L.; Wang, H.; Zhao, W. Appetite suppressing pregnane glycosides from the roots of Cynanchum auriculatum. Phytochemistry 2013, 93, 144–153. [CrossRef]
38. Zhang, J.F.; Li, Y.B.; Qian, S.H.; Li, C.L.; Jiang, J.Q. Study on chemical constituents of Baishouwu. Chin. J. Chin. Pharmacol. 2006, 2006, 814–816.
39. Zhang, X.; Shan, L.; Huang, H.; Yang, X.; Liang, X.; Xing, A.; Huang, H.; Liu, X.; Su, J.; Zhang, W. Rapid identification of acetogenones in two Cynanchum species using liquid chromatography-electrospray ionization tandem mass spectrometry. J. Pharm. Biomed. Anal. 2009, 49, 715–725. [CrossRef]
40. Yeo, H.; Kim, J. A benzoquinone from Cynanchum wilfordii. Phytochemistry 1997, 46, 1103–1105. [CrossRef]
41. He, J.B.; Jia, J.; Gou, H.P.; Zhang, X.M.; Miao, X.S.; He, F.; Tao, J. Chemical constituents of Cynanchum auriculatum. Chin. Med. Mat. 2015, 38, 2318–2320.
42. Uchikura, T.; Tanaka, H.; Sugiwaki, H.; Yoshimura, M.; Sato-Masumoto, N.; Tsujimoto, T.; Uchiyama, N.; Hakamatsuka, T.; Amakura, Y. Preliminary quality evaluation and characterization of phenolic constituents in Cynanchi Wilfordii Radix. Molecules 2018, 23, 656. [CrossRef] [PubMed]
43. Li, J.; Kadota, S.; Kawata, Y.; Hattori, M.; Xu, G.J.; Namba, T. Constituents of the roots of Cynanchum bungei Decne. Isolation and structures of four new glucosides, bungeiside-A, -B, -C, and -D. Chem. Pharm. Bull. 1992, 40, 3133–3137. [CrossRef] [PubMed]
44. Jang, W.; Kim, K.Y.; Kim, K.; Lee, S.C.; Park, H.S.; Lee, J.; Seong, R.S.; Shim, Y.H.; Sung, S.H.; Yang, T.J. The complete chloroplast genome sequence of Cynanchum auriculatum Royle ex Wight (Apocynaceae). Mitochondrial DNA. Part A DNA Mapp. Seq. Anal. 2016, 27, 4549–4550. [CrossRef]

45. Park, H.S.; Kim, K.Y.; Kim, K.; Lee, S.C.; Lee, J.; Seong, R.S.; Shim, Y.H.; Sung, S.H.; Yang, T.J. The complete chloroplast genome sequence of an important medicinal plant Cynanchum wilfordii (Maxim.) Hemsl. (Apocynaceae). Mitochondrial DNA Part A 2016, 27, 3747–3748. [CrossRef]

46. Kim, J.H.; Moon, J.C.; Kang, T.S.; Kwon, K.; Jang, C.S. Development of cpDNA markers for discrimination between Cynanchum auriculatum and Cynanchum auriculatum and their application in commercial C. wilfordii food products. Appl. Biol. Chem. 2017, 60, 79–86. [CrossRef]

47. Kim, C.K.; Kim, Y.K. The multipartite mitochondrial genome of Cynanchum auriculatum (Gentianales: Apocynaceae). Mitochondrial DNA B Resour. 2019, 4, 3360–3361. [CrossRef]

48. Liu, S.; Yi, L.Z.; Liang, Y.Z. Traditional Chinese medicine and medicine science. J. Sep. Sci. 2008, 31, 2113–2137. [CrossRef]

49. Chen, Y.; Yao, F.K.; Ming, K.; Wang, D.Y.; Hu, Y.L.; Liu, J.G. Polysaccharides from traditional Chinese medicines: Extraction, purification, modification, and biological activity. Molecules 2016, 21, 1705. [CrossRef]

50. Mustafa, A.; Turner, C. Pressurized liquid extraction as a green approach in food and herbal plants extraction: A review. Anal. Chim. Acta 2011, 703, 8–18. [CrossRef]

51. Yang, Y.; Khan, B.M.; Zhang, X.P.; Zhao, Y.J.; Cheong, K.L.; Liu, Y. Advances in separation and purification of bioactive polysaccharides through high-speed counter-current chromatography. J. Chromatogr. Sci. 2020, 58, 992–1000. [CrossRef] [PubMed]

52. Liu, Z.; Sun, Y.; Wang, J.; Zhu, H.; Zhou, H.; Hu, J.; Wang, J. Preparative isolation and purification of acetylphens from the Chinese medicinal plant Cynanchum bungei Decne. by high-speed counter-current chromatography. Sep. Purif. Technol. 2008, 64, 247–252. [CrossRef]

53. Sun, Y.; Liu, Z.; Wang, J.; Xiang, L.; Zhu, H. Separation and purification of baishouwubenzophenone, 4-hydroxyacetophenone and 2,4-dihydroxyacetophenone from Cynanchum auriculatum by high-speed counter-current chromatography. Chromatographia 2009, 70, 1–6. [CrossRef]

54. Li, W.; Zhao, L.C.; Sun, Y.S.; Lei, F.J.; Wang, Z.; Gui, X.B.; Wang, H. Optimization of pressurized liquid extraction of three major acetophenones from Cynanchum bungei using a box-behenken design. Int. J. Mol. Sci. 2012, 13, 14533–14544. [CrossRef]

55. Fei, H.R.; Liang, T.J.; Wang, L.A.; Zhou, H.L. Study on extraction and purification technology of C21 steroidal glycosides from root of Cynanchum auriculatum by HSCC. Shizhen Guoqi Guqiao 2015, 26, 1091–1093. [CrossRef]

56. Zhu, H.Q.; Feng, J.; Li, C.Y.; Wu, C.D.; Zhang, M.; Roth, C.M. Optimization of ultrasonic assisted extraction process and structural characterization of Polysaccharide from Baishouwu by Response Surface Methodology. Sci. Technol. Food Ind. 2021, 42, 153–159. [CrossRef]

57. Lee, M.K.; Yeo, H.; Kim, J.; Markelonis, G.J.; Oh, T.H.; Kim, Y.C. Cynandione A from Cynanchum wilfordii and Cynanchum auriculatum and their application in commercial C. wilfordii food products. J. Pharm. Pharmacol. 2000, 52, 341–345. [CrossRef]
70. Sawamoto, A.; Kanazaki, A.; Amakura, Y.; Yoshimura, M.; Masumoto, N.; Uchiyama, N.; Hakamatsu, T.; Okuyama, S.; Furukawa, Y.; Nakajima, M. Cynandione A induces adipogenesis and beige adipocyte-related phenotype in 3T3-L1 cells. *Phytochem. Lett.* 2020, 39, 84–89. [CrossRef]

71. Kim, J.Y.; Lee, J.W.; Lee, J.S.; Jang, D.S.; Shim, S.H. Inhibitory effects of compounds isolated from roots of *Cynanchum wilfordii* on oxidation and glycation of human low-density lipoprotein (LDL). *J. Funct. Foods* 2019, 59, 281–290. [CrossRef]

72. Yang, W.Q.; Chen, X.; Li, Y.L.; Guo, S.F.; Wang, Z.; Yu, X.L. Advances in pharmacological activities of terpenoids. *Nat. Prod. Commun.* 2020, 15, 1934578X29003555. [CrossRef]

73. Zhou, J.L.; Qiu, S.Y.; Chen, X.Y. Properties and research progress of terpenoids in Jatropha curcas. *Guizhou Chem. Ind.* 2008, 2, 11–18.

74. Li, J.L.; Gao, Z.B.; Zhao, W.M. Identification and evaluation of antiepileptic activity of C21 steroidal glycosides from the roots of *Cynanchum wilfordii*. *J. Nat. Prod.* 2016, 79, 89–97. [CrossRef]

75. Debnath, B.; Singh, W.S.; Das, M.; Goswami, S.; Singh, M.K.; Maiti, D.; Manna, K. Role of plant alkaloids on human health: A review of biological activities. *Mater. Today Chem.* 2018, 9, 56–72. [CrossRef]

76. Zhao, Y.; Yan, B.C.; Wang, Z.Y.; Li, M.J.; Zhao, W. Natural polysaccharides with immunomodulatory activities. *Mini Rev. Med. Chem.* 2020, 20, 96–106. [CrossRef]

77. Xu, Y.; Ren, R. Isolation and physico-chemical properties of polysaccharides from the root of *Cynanchum auriculatum* Royle ex Wight. *China J. Chin. Mat. Med.* 1991, 16, 163–166.

78. Jang, M.; Lim, T.G.; Lee, E.; Hong, H.D.; Rhee, Y.K.; Lee, Y.J.; Lee, J.H.; Cho, C.W. Immunostimulatory activities of a high molecular weight fraction of *Cynanchum auriculatum* Royle ex Wight root obtained by ultrafiltration. *Pharmacogn. Mag.* 2020, 16, 493–498. [CrossRef]

79. Cho, C.W.; Ahn, S.; Lim, T.G.; Hong, H.D.; Rhee, Y.K.; Yang, D.C.; Jang, M. *Cynanchum wilfordii* polysaccharides suppress dextran sulfate sodium-induced acute colitis in mice and the production of inflammatory mediators from macrophages. *Mediat. Inflamm.* 2017, 2017, 859586. [CrossRef] [PubMed]

80. Chai, Z.; Huang, W.; Zhao, X.; Wu, H.; Zeng, X.; Li, C. Preparation, characterization, antioxidant activity and protective effect of polysaccharides from *Cynanchum auriculatum* Royle ex Wight. *Int. J. Biol. Macromol.* 2018, 119, 1068–1076. [CrossRef] [PubMed]

81. Zhang, R.; Ye, Y.; Shen, Y.; Liang, H. Studies on cytotoxic constituents of *Cynanchum auriculatum* Royle ex Wight. *Acta Pharm. Sinica* 2000, 35, 431–437.

82. Lu, Y.; Teng, H.L.; Yang, G.Z.; Mei, Z.N. Three new steroidal glycosides from the roots of *Cynanchum auriculatum*. *Molecules* 2011, 16, 1901–1909. [CrossRef] [PubMed]

83. Song, J.M.; Tao, G.J.; Tang, J.; Ding, X.L. Isolation and characterization of C21 steroidal glycosides from *Cynanchum auriculatum*. *J. Wuxi Univ. Light Ind.* 2002, 21, 176–178.

84. Li, Z.G.; Wu, J.; Chen, S.Q.; Zhu, L.; Jiang, R.; Cai, Y.S. One new C21 steroidal compound from *Cynanchum auriculatum*. *Chin. Tradit. Herbal Drugs* 2020, 51, 5921–5923.

85. Gan, H.; Xiang, W.J.; Ma, L.; Hu, L.H. Six new C21 steroidal glycosides from *Cynanchum bungei* Dence. *Helv. Chim. Acta* 2008, 91, 2222–2234. [CrossRef]

86. Qin, J.J.; Chen, X.; Lin, Z.M.; Xu, Y.S.; Li, Y.M.; Zuo, J.P.; Zhao, W.M. C21-steroidal glycosides and sesquiterpenes from the roots of *Cynanchum bungei* and their inhibitory activities against the proliferation of B and T lymphocytes. *Fitoterapia* 2018, 124, 193–199. [CrossRef]

87. Hao, S.J.; Gao, L.J.; Xu, S.F.; Ye, Y.P.; Li, X.Y. Six new steroidal glycosides from roots of *Cynanchum bungei*. *Phytochem. Lett.* 2018, 23, 26–32. [CrossRef]

88. Xiang, W.J.; Ma, L.; Hu, L.H. C21 Steroidal glycosides from *Cynanchum wilfordii*. *Helv. Chim. Acta* 2009, 92, 2659–2674. [CrossRef]

89. Zhao, J.W. Taishan Baishouwu: Isolation and Identification of C21 Steroids and Their Inhibition of Hedgehog Signaling Pathway Activity. Master’s Thesis, Zhejiang Academy of Medical Sciences, Hangzhou, China, 2017.

90. Zhang, M.; Wang, D.; Li, B. Neuroprotection of two C21 steroidal glycosides from *Cynanchum auriculatum* against H2O2-induced damage on PC12 cells. *Nat. Prod. Res.* 2019, 35, 1752–1755. [CrossRef]

91. Li, X.Y.; Zhou, L.F.; Gao, L.J.; Wei, Y.; Xu, S.F.; Chen, F.Y.; Huang, W.J.; Tan, W.F.; Ye, Y.P. Cynanchbungeigenin C and D, a pair of novel epimers from *Cynanchum bungei*, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli. *Cancer Lett.* 2018, 420, 195–207. [CrossRef]

92. Peng, Y.R.; Li, Y.B.; Liu, X.D.; Zhang, J.F.; Duan, J.A. Antitumor activity of C21 steroidal glycosides from *Cynanchum auriculatum* Royle ex Wight. *Phytotherapy* 2008, 15, 1016–1020. [CrossRef]

93. Zhang, R.; Liu, Y.; Wang, Y.; Ye, Y.; Li, X. Cytotoxic and apoptosis-inducing properties of auriculoside A in tumor cells. *Chem. Biodivers.* 2007, 4, 887–892. [CrossRef]

94. Chen, J.J.; Zhang, Z.X.; Zhou, J. Structures of cynauricuside A, B and C. *Acta Bot. Yunnanica* 1990, 2, 197–210.

95. Hwang, B.Y.; Kim, S.E.; Kim, Y.H.; Kim, H.S.; Hong, Y.S.; Ro, J.S.; Lee, K.S.; Lee, J.J. Pregnane glycoside multidrug-resistance modulators from *Cynanchum wilfordii*. *J. Nat. Prod.* 1999, 62, 640–643. [CrossRef]

96. Hayashi, K.; Mitsuhashi, H. Studies on the constituents of Asclepiadaceae plants: Aglycones from *Cynanchum wilfordii* HEMSLEY. *Chem. Pharm. Bull.* 1975, 23, 139–143. [CrossRef]
123. Lee, H.S.; Choi, J.H.; Kim, Y.E.; Kim, I.H.; Kim, B.M.; Lee, C.H. Effects of the *Cynanchum wilfordii* ethanol extract on the serum lipid profile in hypercholesterolemic rats. *Prev. Nutr. Food Sci.* 2013, 18, 157–162. [CrossRef]

124. Kim, S.H.; Lee, T.H.; Lee, S.M.; Park, J.H.; Park, K.H.; Jung, M.; Jung, H.; Mohamed, M.A. A.; Baek, N.I.; Chung, I.S.; et al. Cynandione A attenuates lipopolysaccharide-induced production of inflammatory mediators via MAPK inhibition and NF-κB inactivation in RAW264.7 macrophages and protects mice against endotoxin shock. *Exp. Biol. Med.* 2015, 240, 946–954. [CrossRef]

125. Koo, H.J.; Sohn, E.H.; Pyo, S.; Woo, H.G.; Park, D.W.; Ham, Y.M.; Jang, S.A.; Park, S.Y.; Kang, S.C. An ethanol root extract of *Cynanchum wilfordii* containing acetophenones suppresses the expression of VCAM-1 and ICAM-1 in TNF-α-stimulated human aortic smooth muscle cells through the NF-κB pathway. *Int. J. Mol. Med.* 2015, 35, 915–924. [CrossRef]

126. Wu, Z.; Wang, Y.; Meng, X.; Wang, X.; Li, Z.; Qian, S.; Wei, Y.; Shu, L.; Ding, Y.; Wang, P.; et al. Total C21 steroid glycosides, isolated from the root tuber of *Cynanchum auriculatum* Royle ex Wight, attenuate hydrogen peroxide-induced oxidative injury and inflammation in L02 cells. *Int. J. Mol. Med.* 2018, 42, 3157–3170. [CrossRef] [PubMed]

127. Ji, C.X.; Li, X.Y.; Jia, S.B.; Liu, L.L.; Ge, Y.C.; Yang, Q.X.; Zhang, J.J. The antidepressant effect of *Cynanchum auriculatum* in mice. *J. Pharm. Bio. 2012*, 50, 1067–1072. [CrossRef] [PubMed]

128. Huang, L.J.; Wang, B.; Zhang, J.X.; Yuan, C.M.; Gu, W.; Mu, S.Z.; Hao, X.J. Synthesis and evaluation of antifungal activity of C21-steroid derivatives. *Bioorg. Med. Chem. Lett.* 2016, 26, 2040–2043. [CrossRef] [PubMed]

129. Yang, X.Y.; Liu, A.L.; Liu, S.J.; Xu, X.W.; Huang, L.F. Screening for neuraminidase inhibitory activity in traditional Chinese medicines used to treat influenza. *Molecules* 2016, 21, 1138. [CrossRef]

130. Kim, M.S.; Baek, J.H.; Park, J.A.; Hwang, B.Y.; Kim, S.E.; Lee, J.J.; Kim, K.W. Wilfoside K1N isolated from *Cynanchum wilfordii* inhibits angiogenesis and tumor cell invasion. *Int. J. Oncol.* 2005, 26, 1553–1559. [CrossRef]

131. Lee, G.; Kim, J.; Pan, S.O.; Kim, M.; Jun, W.; Choi, C.Y. Aphrodisiac property of the aqueous extract of *Cynanchum wilfordii*. *Food Nutr. Res.* 2016, 4, 713–719. [CrossRef]

132. Lee, G.; Shin, J.; Choi, H.; Je, A.; Pan, S.; Bae, D.; Lee, Y.; Choi, C. *Cynanchum wilfordii* ameliorates testosterone-induced benign prostatic hyperplasia by regulating 5α-reductase and androgen receptor activities in a rat model. *Nutrients* 2017, 9, 1070. [CrossRef]

133. Jun, W.; Choi, Y.; Lee, G.; Pan, S.; Kim, J. Bone regenerative effect of aqueous *Cynanchum wilfordii* extract in receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and estrogen deficiency-induced osteoporosis. *Int. J. Phytomed.* 2017, 9, 461–470. [CrossRef]

134. Lee, H.; Kim, M.H.; Choi, Y.Y.; Hong, J.; Yang, W.M. Effects of *Cynanchum wilfordii* on osteoporosis with inhibition of bone resorption and induction of bone formation. *Mol. Med. Rep.* 2018, 17, 3758–3762. [CrossRef]

135. Luo, Y.; Sun, Z.G.; Li, Y.B.; Liu, L.N.; Cai, X.T.; Li, Z.L. Caudatin inhibits human hepatoma cell growth and metastasis through modulation of the Wnt/β-catenin pathway. *OncoL. Rep.* 2013, 30, 2923–2928. [CrossRef] [PubMed]

136. Park, K.H.; Kim, J.; Lee, E.H.; Lee, T.H. Cynandione A inhibits lipopolysaccharide-induced cell adhesion via suppression of the protein expression of VCAM-1 in human endothelial cells. *Int. J. Mol. Med.* 2018, 41, 1756–1764. [CrossRef] [PubMed]

137. Saitou, T.; Imamura, T. Quantitative imaging with Fucci and mathematics to uncover temporal dynamics of cell cycle progression. *Dev. Growth Diff. 2016*, 6, 6–15. [CrossRef]

138. Fei, H.R.; Chen, H.L.; Xiao, T.; Chen, G.; Wang, F.Z. Caudatin induces cell cycle arrest and caspase-dependent apoptosis in HepG2 cell. *Mol. Biol. Rep.* 2012, 39, 131–138. [CrossRef]

139. Fu, X.Y.; Zhang, S.; Yang, M.F.; Fan, C.D.; Sun, B.L.; Wang, K.; Sun, B.L. Caudatin inhibits human glioma cells growth through triggering DNA damage-mediated cell cycle arrest. *Cell. Mol. Neurol. Bi.* 2015, 35, 953–959. [CrossRef]

140. Lowe, S.W.; Lin, A.W. Apoptosis in cancer. *Carcinogenesis* 2000, 21, 485–495. [CrossRef] [PubMed]

141. Pai, P.; Sukumar, S. HOX genes and the NF-kappa B pathway: A convergence of developmental biology, inflammation and cancer biology. *Biochim. Biophys. Acta Rev. Cancer* 2020, 1874, 188450. [CrossRef]

142. Napetschnig, J.; Wu, H. Molecular basis of NF-kappa B signaling. *Annu. Rev. Biophys.* 2013, 42, 443–468. [CrossRef] [PubMed]

143. Yang, S.B.; Lee, S.M.; Park, J.H.; Lee, T.H.; Baek, N.I.; Park, H.J.; Lee, H.; Kim, J. Cynandione A from *Cynanchum wilfordii* attenuates the production of inflammatory mediators in LPS-induced BV-2 microglial cells via NF-κB inactivation. *Biol. Pharm. Bull.* 2014, 37, 1390–1396. [CrossRef] [PubMed]

144. Shiryaev, A.; Moens, U. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: Menage a trois or menage a quatre? *Cell. Signal.* 2010, 22, 1185–1192. [CrossRef] [PubMed]

145. Huang, Q.; Mao, X.F.; Wu, H.Y.; Liu, H.; Sun, M.L.; Wang, X.; Wang, Y.X. Cynandione A attenuates neuropathic pain through p38 MAPK-mediated spinal microglial expression of β-endorphin. *Brain Behav. Immun.* Health 2017, 62, 64–77. [CrossRef]

146. Fei, H.R.; Yuan, C.; Wang, G.L.; Zhao, Y.; Li, Z.J.; Du, X.; Wang, F.Z. Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5. *Phytomedicines* 2019, 62, 152950. [CrossRef] [PubMed]

147. Jang, M.; Cho, C.W.; Han, A.R.; Rhee, Y.K.; Hong, H.D.; Kim, K.T.; Lee, S.Y.; Lee, K.M.; Jung, S.K.; Lim, T.G. MMP-1 suppressing activity of high-molecular weight fraction isolated from the roots of *Cynanchum wilfordii*. *J. Funct. Foods* 2018, 40, 329–335. [CrossRef]
149. Harb, J.; Lin, P.J.; Hao, J.J. Recent development of Wnt signaling pathway inhibitors for cancer therapeutics. *Curr. Oncol. Rep.* 2019, 21, 12. [CrossRef] [PubMed]

150. Fallah, A.; Sadeghinia, A.; Kahroba, H.; Samadi, A.; Heidari, H.R.; Bradaran, B.; Zeinali, S.; Molavi, O. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. *Biomed. Pharmacother.* 2019, 110, 775–785. [CrossRef]

151. Wang, X.Z.; Fu, X.T.; Zhao, S.J.; Fu, X.Y.; Zhang, H.F.; Shao, L.R.; Li, G.; Fan, C.D. Antiangiogenic properties of caudatin in vitro and in vivo by suppression of VEGF-VEGFR2-AKT/FAK signal axis. *Mol. Med. Rep.* 2017, 16, 8937–8943. [CrossRef]

152. Choi, D.H.; Lee, Y.J.; Oh, H.C.; Cui, Y.L.; Kim, J.S.; Kang, D.G.; Lee, H.S. Improved endothelial dysfunction by *Cynanchum wilfordii* in apolipoprotein E-/- mice fed a high fat/cholesterol diet. *J. Med. Food* 2012, 15, 169–179. [CrossRef]

153. Yellepeddi, V.; Rower, J.; Liu, X.X.; Kumar, S.; Rashid, J.; Sherwin, C.M.T. State-of-the-Art review on physiologically based pharmacokinetic modeling in pediatric drug development. *Clin. Pharmacokinet.* 2019, 58, 1–13. [CrossRef]

154. Zhang, Y.P.; Shan, L.; Xu, W.; Yang, M.; Zhang, W.D.; Li, H.Y. LC-MS/MS method for the determination of cynandione A in rat plasma and tissues. *Biomed. Chromatogr.* 2008, 22, 1173–1179. [CrossRef] [PubMed]

155. Zhu, Q.Q.; Hu, Y.Y.; Shan, Y.Y.; Wang, Y.Y.; Wu, X.L.; Mao, B.P.; Ge, R.S. Determination of caudatin in rat plasma by UPLC-MS/MS: Application to a preclinical pharmacokinetic study. *Pharmacology* 2015, 96, 49–54. [CrossRef] [PubMed]

156. Peng, Y.R.; Li, Y.B.; Wang, D.W.; Liu, X.D.; Zhang, J.F.; Qian, S.H.; Duan, J.N. Determination of caudatin-2,6-dideoxy-3-O-methyl-β-D-cymaropyranoside in rat plasma using liquid chromatography-tandem mass spectrometry. *Biomed. Chromatogr.* 2008, 22, 575–580. [CrossRef] [PubMed]

157. Xu, W.; Shan, L.; Liu, X.; Li, H.; Hu, L.; Zhang, W. Determination of two C21 steroidal glycosides of Baishouwu and their metabolites in mice plasma and tumor homogenate by liquid chromatography-tandem mass spectrometry. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* 2008, 876, 203–210. [CrossRef] [PubMed]

158. Rao, D.R.; Sordillo, J.E.; Kopel, L.S.; Gaffin, J.M.; Sheehan, W.J.; Hoffman, E.; Ozonoff, A.; Gold, D.R.; Phipatanakul, W. Eosinophilic esophagitis associated with *Cynanchum wilfordii*. *Ann. Allergy. Asthma. Immunol.* 2015, 114, 257–265. [CrossRef]

159. Youn, J.S.; Ham, Y.M.; Yoon, W.J.; Choi, H.C.; Lee, J.E.; Cho, B.; Kim, J.Y. *Cynanchum wilfordii* etanolic extract controls blood cholesterol: A double-blind, randomized, placebo-controlled, parallel trial. *Nutrients* 2019, 11, 836. [CrossRef] [PubMed]

160. Shin, S.M.; Cho, Y.M.; Kwon, J.E.; Lee, S.R.; Kang, S.C. Supplementation with *Cynanchum wilfordii* radix extract for 8 weeks lowers serum total cholesterol: A controlled, randomized, double-blind clinical trial. *Phytother. Res.* 2020, 34, 2313–2322. [CrossRef]